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CHAPTER 1 
INTRODUCTION 
History 
After the first indication for the presence of lactogenic activity in pituitary extracts 
was demonstrated by Strieker and Grueter in 1928, Riddle et al. (1933) gave 
the name prolactin to the substance responsible for this activity. 
The same effect was shown in the experiments on the sheep's pituitary by White 
et al. ( 1937). It was only in 1963 that it became clear (Riddle et al.) that prolactin, 
as well as the stimulating influence on milkproduction by the mammae, had 
a wide array of effects on different organs. Nicoli and Bern in their review 
article (1972) gave a summary of the multiple effects of prolactin in different 
species from reptiles to vertebrates, not yet including mankind (table 1). The 
presence of prolactin in man had been supposed, but could not been demonstrated 
with certainty. This is in part due to the fact that growth hormone (isolated 
from humans by Chadwick et al. in 1961) possesses a relatively strong lactogenic 
activity and is produced in large quantities from the anterior pituitary. In the 
early bio-assays of the nineteensixties, the lactogenic activity of growth hormone 
was measured and could not be separated from a possible contribution of prolactin. 
It was to take approximately 10 years from 1961 before the existence of human 
prolactin was proven, despite the experiments of Pasteeis in 1963, which showed 
prolactin producing cells in the human anterior pituitary. Frantz et al. (1972a) 
identified prolactin as a separate protein. In their in vitro studies the lactogenic 
activity in human serum was inhibited by an anti-serum directed against sheep's 
prolactin, but not by an anti-serum against growth hormone. 
Finally, however. Friesen et al. (1970) undeniably proved in the monkey and 
in humans that prolactin is a separate entity next to growth hormone. Hereafter 
prolactin was isolated in sufficient quantities (Hwang et al. 1971, Lewis et al. 
1971, Friesen et al. 1972) and the development of a specific radioimmunoassay 
followed rapidly. 
Molecular structure 
Human prolactin consists of a simple protein-chain of 198 aminoacids linked 
by three disulfide bridges which are a typical feature of the prolactin molecule 
(Shome and Parlow 1977). The similarity with growth hormone (hGH) and 
placental lactogen (hPL) is present only for 16% and 13% respectively, which 
is remarkable in view of their strong lactogenic activity (figure 1 ). 
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Table I Summary of actions of prolactin 
Actions of prolactin related to reproduction 
Mammals 
Mammary development and lactation 
Preputial gland size and activity 
Synergism with androgen on male sex 
accessory glands 
Luteotrophic 
Luteolytic action in rats and mice 
Fertility in dwarf mice 
Increased testis cholesterol 
Increased androgen binding in human prostate 
Stimulation of gluceromdase activity in 
rodent testis 
Parental behaviour 
Decreased copulatory activity in male rabbits 
Advanced puberty in rats 
Vaginal mucifìcation in rats 
Antiovulatory and antilutemizmg in rats 
Relaxation of utenne cervix in rats 
Reduced catabolism of progesterone by rat 
uterus 
Inhibition of myometnal contractions 
Increased estradiol binding by rat uterus 
Actions of prolactin involving water and 
electrolyte balance 
MammaL· 
Lactation 
Increased Na+ retention at renal level 
Corticotropic 
Actions of prolactin on integumentary 
(Ectodermal) structures 
MammaL· 
Mammary development and lactation 
Sebaceous and preputial gland size and 
activity 
Hair maturation 
Actions of prolactin involving growth promotion 
Mammals 
Mammary development 
Sebaceous & preputial gland growth 
Hair growth 
Frytropoietic 
Renotrophic 
Spermatogenic 
Male sex accessory development 
Luteotrophic 
Growth hormone like metabolic 
actions 
Effects on lipid deposition and /or 
mobilization reported in teleost, 
amphibians, reptiles, birds and 
mammals 
Hyperglycemic-diabetogenic action 
reported in amphibians, birds and 
mammals 
Effects on blood urea nitrogen (BUN) 
N balance, blood glucose, free fatty 
acid (FFA), and calcium metabolism 
in humans similar to HGH 
Actions of prolactin involving synergism 
with steroid hormones or on organs also 
influenced by steroids 
MammaL· 
Mammary growth (ovarian steroids) 
Milk secretion (corticosteroids) 
Sebaceous and preputial gland secretion 
(gonadal and cortical steroids) 
Growth and secretion of male sex 
accessory glands (androgens) 
Luteotrophic action (estrogens'') 
Renal Na+ reabsorption 
(aldosterone'') 
and renotrophic (androgens) 
Spermatogenesis (androgens) 
Advanced puberty (gonadal steroids) 
Hair growth (androgens, corticosteroids) 
Vaginal mucifìcation in rats (estrogen and 
progesterone) 
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Prolactin 
Ovine Human 
2 9 %
 13% 
Placental 
lactogen 
Growth 
hormone 
/ 59% 85% 
HO-ft У^ 1 HO-|v 
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Figure 1 Comparison!, between the structures of ovine and human prolactin, placental lactogen 
and growth hormone Diagrams indicate the positions of disulphide bonds (heavy bars) and of 
tryptophan residues (T) Figures indicated the percentages of identical amino acid pairs between 
hormones Gaps have been introduced into the sequences to maximize identity 
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Serum prolactin is apparent in three forms: small prolactin with a molecular 
weight of about 23,000 Dalton, big prolactin of 40,000-50,000 Dalton and big-
big prolactin of more than 60,000 Dalton (Suh and Frantz 1974). The large 
molecules probably are formed by aggregation in the serum after excretion of 
small molecules by the pituitary. Nowadays serum prolactin is measured by 
specific and sensitive radioimmunoassays. 
Physiobgy 
Of all the pituitary hormones, prolactin seems to be the most versatile as it 
influences many physiological processes (Nicoli 1974, Leong et al. 1983). Its 
role in the lactogenesis and galactopoiesis is one of paramount importance in 
the life of the neonate and thus in the survival of the species. 
The prolactin producing cell is named lactotropic cell, analogous to for instance, 
gonadotropic cells. Herlant and Pasteéis (1967) identified the prolactin producing 
cell for the first time by means of the light-microscope and his findings were 
later confirmed by Pasteéis (1972) with the help of immunocytochemical methods. 
In the hormone secretive pituitary 40-50% of all cells consist of lactotropic 
cells both in females and in males according to studies and calculations with 
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the use of immunocytochemical anti-sera and the 'reverse hemolytic plaque assay-
technique' (Lugue et al. 1986). It is generally assumed that lactotropic cells 
are spread throughout the pituitary in clusters of 5 to 10 cells. Recently, Papka 
et al. ( 1986) showed that in the rat they are grouped in two zones, a thin peripheral 
layer and a more pronounced central layer. 
With the 'reverse hemolytic plaque assay', Hymer et al. (1974) discovered a 
correlation between the size of the cell and the amount of prolactin secreted 
by it. With the help of this technique Neill et al. (1987) suggested the existence 
of two sorts of cells: one that produces a large quantity of prolactin and one 
that secretes a small quantity. The cells that secrete a larger quantity of prolactin 
would be more directly controlled by the hypothalamus whereas the smaller 
quantity producing cells would act more autonomously. Lactotropic cells of the 
peripheral layer are in general smaller and less under hypothalamic control 
compared to cells of the central layer. The latter are able, due to the size and 
hypothalamic regulation, to produce more prolactin (Boockfor and Frawley 1987). 
More investigation is required to clarify whether these differences in prolactin 
secretion are caused by extrinsic factors such as interaction with surrounding 
cells (Sato 1980) or by intrinsic factors such as stage of cell cycle (Snyder et 
al. 1978). 
After Harvis' hypothesis that the pituitary is controlled by the hypothalamus 
(1955), similar suggestions were made regarding the regulation of prolactin. 
Everett (1954 and 1956) supposed the existence of a hypothalamic factor which 
would reach the anterior pituitary via the portal system, thus inhibiting prolactin 
secretion. He based his hypothesis on the observation of an increased prolactin 
secretion in the, from the hypothalamus isolated, pituitary. Pasteéis (1963) 
additionally showed a decrease in prolactin secretion when hypothalamic extracts 
were added to the culture medium. Meites et al. (1963) confirmed the existence 
of a prolactin inhibiting factor (PIF) in these hypothalamic extracts. Macleod 
(1976) finally proved the presence of PIF as dopamine which in the hypothalamus, 
acts amongst others as neurotransmitter. This conclusion was reached after 
quantitative measurement of dopamine from the bloodvessels in the stem of 
the pituitary, disregarding the large contribution of dopamine from the posterior 
pituitary via the short portal circulation (Ben-Jonathan 1980). By the demon-
stration of the presence of dopamine receptors on the lactotropic cell membranes, 
Goldsmith et al. (1979) confirmed that on cellular level prolactin secreting cells 
are (in part) regulated by dopamine. 
One had hypophesized the existence of prolactin inhibiting factors other than 
dopamine for a long time. Gamma Amino Butyric-Acid (GABA) (Enjalbert et 
al. 1979) and Gonadotropin releasing hormone Associated Peptide (GAP) 
(Nikolics et al. 1985) have been mentioned, but until now no definite proof 
has been given for their role in the regulation of prolactin secretion. 
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Nipple Stimulation, in particular during the Puerperium, gives rise to strong 
prolactin secretion (Neill 1974). Acute stress has the same effect, although to 
a lesser extent (Neill 1970). This is despite the fact that there is no clear evidence 
for the existence of a separate prolactin releasing hormone. After two minutes 
of nipple stimulation there is already a marked increase in serum prolactin 
concentration. An obvious explanation for this neurogenic stimulation would 
be dehibition of hypothalamic influence, resulting in an immediate decrease in 
dopamine secretion (Chiocchio et al. 1979). However, the decrease of dopamine 
concentration measured in the portal blood circulation after nipple stimulation 
has been found too small to explain the increase in prolactin secretion (Plotsky 
and Neill 1982). Hypothalamic dopamine secretion has even appeared to be 
rather insensitive to prolactin increasing stimuli such as suckling (de Greef et 
al. 1981).A more convincing argument in support of a prolactin releasing factor 
is the fact that removal of the posterior pituitary counteracts the increase of 
prolactin after suckling without changing basic prolactin concentrations (Murai 
and Ben-Jonathan 1987). Other substances can be demonstrated in the portal 
system such as thyreotrope releasing hormone (TRH) (Leong and Neill 1987), 
vaso-active intestinal peptides (VIP) (Abe et al. 1985) and oxytocin (Samson 
et al. 1986). Their concentrations change little after nipple stimulation and they 
therefore seem not responsible for the increase in prolactin secretion. 
Many neuropeptides, amongst others serotonin and several endorphins seem to 
play a role in the hormonal regulation of production and secretion of prolactin 
and gonadotropins. A prolactin releasing factor, however, has not been recognized 
and described as yet. Murai and Ben-Jonathan (1987) suggested that such a 
substance would derive from or be mediated by the neurosecretive pituitary. 
Next to the regulation of prolactin secretion by the hypothalamus, paracrine 
and autocrine mechanisms are also possible. VIP can be synthesized in the 
lactotropic cell (Arnaout et al. 1986); it stimulates prolactin secretion. It is possible 
that dopamine counteracts the effects of VIP or inhibits the secretion of VIP; 
in this field more research is necessary. Aguilera et al. (1982) found that 
angiotensine 2 is also able to enhance prolactin secretion by the lactotropic 
cell. It is being synthesized by gonadotropic cells after GnRH stimulation (Denef 
et al. 1986). Physiological consequences of these paracrine regulations are not 
clear as yet, but they may play a role in the more chronic changes of prolactin 
secretion such as found after, for instance, oestrogen stimulation. 
One can conclude that the lactotropic cell is responsible for the synthesis, storage 
and secretion of prolactin (Farquhar et al. 1975). The synthesis and secretion 
are influenced by TRH, VIP as well as dopamine via the same second messengers 
such as cyclic AMP, calcium and some phosphoinositides. The receptors for 
TRH, VIP and dopamine are all membrane-bound (Murodoch et al. 1985). 
Dopamine exerts its action mainly by inhibiting cyclic AMP (Swennen and Denef 
1982), whereas VIP stimulates the production of cyclic AMP (Nagy et al. 1987). 
On the other hand, TRH acts via calcium and phosphoinositides (Martin 1985). 
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These autocrine, paracrine and endocrine regulation systems collaborate har-
moniously in their control by influencing the synthesis, storage and secretion 
of prolactin. 
PATHOLOGY 
Most substances which cause a hyperprolactinaemia inhibit dopamine synthesis 
or block dopamine-receptors on hypothalamic or pituitary level (Frantz et al. 
1972a, Benmont et al. 1974, Gold et al. 1977, Carlson and Ippoliti 1977, Másala 
et al. 1980, del Pozo and Köbberling 1981). The reverse, hypoprolactinaemia 
seems to be non-existent as well in clinical experience as in the literature. One 
has suggested (Schulz et al. 1976, del Pozo et al. 1979) that hypoprolactinaemia 
would also give rise to an insufficient luteal phase, but this has never been 
confirmed. In contrast, hyperprolactinaemia is found frequently and the incidence 
given in the literature vanes between 11% and 47% with a mean of 24,2% 
in women with secondary amenorrhoea (Flückiger et al. 1981; table 2). It was 
Table 2 Incidence of hyperprolactinaemia in secondary amenorrhoea 
Reference No of Patients Hyperpro- Galactorrhea as 
lactinemia % of hyperpro-
(%) lactinemia 
Franks et al (1975) 
Seppalaetal (1975) 
Canales et al (1976a) 
Bohnetetal (1976) 
Jurgensen et al (1976) 
Rjosketal (1976) 
Berghetal (1977) 
Seppalaetal (1977) 
Shearman and Fraser (1977) 
Leyendecker et al (1977) 
Lunenfeldetal(1980) 
40 
34 
116 
127 
305 
445 
287 
123 
90 
50 
352 
Σ1969 
20 
47 
28 
13 
II 
16 
15 
33 
39 
24 
21 
35 
53 
0 
53 
-
89 
87 
38 
83 
66 
52 
Mean and range 24 2(11-47) 55 5(0/35-89) 
From Prolaclin Physiology, Pharmacology and Clinical Findings Monographs on Endocrinology Fluckiger E, del Po/o E, von 
Werder К 1982,118 
initially thought that hyperprolactinaemia could be recognized in the galactor-
rhoea /amenorrhoea syndromes, of which the most well known is the Chiari-
Frommel syndrome described in 1855 (Chiari et al. 1855). Pathognomonic is 
the persistence of postpartum lactation together with amenorrhoea. Frommel 
described the syndrome again and he added more clinical data (Frommel 1882). 
Argonz and del Castillo (1953) mentioned the same syndrome though unrelated 
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to pregnancy. In the description of this syndrome by Forbes et al. (1954), the 
frequent incidence of pituitary tumours was noted. At present it is clear that 
in a case of galactorrhoea with amenorrhoea, hyperprolactinaemia is a very 
probable cause. However, not all patients with hyperprolactinaemia show 
galactorrhoea. Changes in the menstrual cycle appear to be a more sensitive 
parameter than galactorrhoea as a symptom of hyperprolactinaemia (Seppälä 
et al. 1977). Hyperprolactinaemia can be triggered by the use of drugs but it 
can also be found in some forms of hypothyroidism (Samaan et al. 1977, 
Yamamoto et al. 1983). It is well known that TRH has a prolactin stimulating 
action and in the case of primary hypothyroidism one can expect a minor or 
moderate degree of hyperprolactinaemia. A long standing exposure to oestrogens 
can also give rise to a mild hyperprolactinaemia by a direct influence on lactotropic 
cells (Frantz et al. 1972b). This, of course is only true for exogenous oestrogens 
as otherwise hyperprolactinaemia would give a hypogonadotropic status. In most 
of the cases there is no clear cause for the hyperprolactinaemia (see table 3). 
In many instances there is a tumorous growth of prolactin producing cells in 
the pituitary which could produce a so called micro- or macro-adenoma (Thorner 
1977, von Werder and Rjosk 1979). It remains unclear which is cause and which 
is consequence: with a continuous malfunctioning of these cells by insufficient 
Table 3 Causes of elevated serum prolactin concentrations 
Physiobgical 
Pregnancy and post partum 
Pathobgical 
Hypothalamic lesions (traumatic, inflammatory and neoplastic hypothalamic disorders) 
Stalk section 
PRL· secreting pituitary tumours 
Non PRL·secreting tumours impinging upon the pituitary stalk 
Hypothyroidism 
Hypo-hypercortisolism 
Chronic renal failure 
Liver cirrhosis 
Chronic mfíltatnve processes of the mammary gland and the chest 
Idiopathic 
Pharmacological 
Antagonists of dopamine neurotransmission 
Agonists of serotonin neurotransmission 
Antagonists of histamine H2 receptors 
Opiates 
Sex steroids 
From Pathophysiology of hyperprolactinaemic states Millier F In Gynecological Endocrinology Genazzani A, Volpe A, Facchinetti 
F(cds). 198721Λ 
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inhibition (due to a shortage of PIF or PIF insensitivity of the cells) a hypertrophia 
or formation of an adenoma is possible. 
Other endocrine disregulations can be present, dependent on the increase of 
serum prolactin concentration. In general the FSH value is normal or slightly 
raised, whilst LH concentration is low-normal or even decreased with a slowly 
diminishing pulsatile excretion. As a result follicles will not mature and steroid 
production by the ovary will gradually stop, eventually leading to a hypo-
oestrogenic status. 
A mild hyperprolactinaemia will rather cause an insufficient luteal phase, but 
later anovulatory cycles can occur and eventually with a sufficient rise in prolactin 
concentration, secondary amenorrhoea. The influence of hyperprolactinaemia 
in androgen metabolism is not clear: in the literature a mild increase of DHEAS 
is often mentioned but is not a consistent finding (Carter et al. 1977; Turpin 
et al. 1979). A summary of effects on inappropiately increased prolactin secretion 
is given in table 4. 
Table 4. Effects on inappropriately increased prolactin secretion 
Females 
Clinical Failure to enter menarche 
Galactorrhoea with ovulatory cycles 
Short luteal phase 
Menomethorrhagia 
Anovulatory cycles 
Amenorrhoea' 
Hirsutism 
Biochemical Elevated plasma PRL concentrations 
Lack of sleep-related PRL elevations 
Absence of LH pulsatility 
Lack of positive estrogen feedback on LH 
Low basal estrogens'1 
Elevated androgenic adrenal steroids 
Positive pituitary and ovarian response to exogenous stimulation 
Clomiphene resistance 
Males 
Clinical 
Biochemical 
Failure to enter puberty 
Galactorrhoeac 
Oligoapermia, subfertility 
Signs of androgen failure 
Elevated plasma PRL concentrations 
Lack of PRL elevations dunng sleep 
Low androgen production 
Positive pituitary and testicular response to exogenous stimulation 
"Not necessarily associated with galactorrhoea 
•"Subjected to variance: Normal basal estrogens with normal or even elevated FSH are not uncommon 
cLess frequent in males probably due to reduced mammary tissue mass. 
brom Prolactin Physiology, Pharmacology and Clinical Findings Monographs on Endocnnology Fldckiger E, de] Pozo E, von 
Werder К 1982.124 
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TREATMENT 
When hyperprolactinaemia is diagnosed and treatment considered, this can be 
surgical (Derome et al 1979) or medical (Thorner 1977) or a combination 
of both (Landolt et al 1979) Initially radiation has been used (such as indium 
implantation) (Kelly et al 1978), but this method is almost obsolete (Samaan 
et al 1979, Besseretal 1977) 
There is a decreasing tendency towards surgical therapy the procedure is 
extremely tedious and there is a large chance of reoccurrence (Derome et al 
1979) Although there is still discussion about the right policy in case of a macro-
prolactinoma, it is generally accepted that a micro-adenoma or a hyperpro-
lactinaemia without a tumour should be treated medically 
Even before the discovery of human prolactin, experiments had started with 
the dopamine-agomst bromocriptine (figure 2), which, as appeared later, is bound 
specifically to dopamine receptors of the lactotropic cell and blocks the secretion 
of prolactin Subsequently synthesis also stops With hyperprolactinaemia, a 
dosage of 5 to 7 5 mg of bromocriptine (Parlodel8) is generally sufficient The 
dosage is increased stepwise until the effect is reached 
H3C 
C — N H · 
CH OH 
• CM^SOjH 
Figure 2 Structural formula of bromocnptme 
Since the introduction of bromocnptme, its potent prolactin reducing ability has 
been confirmed in many publications In gynaecological patients this drug is 
especially prescribed in case of menstrual cycle disturbances with or without 
the desire of pregnancy Due to its dopaminergic effects, the administration of 
bromocnptme can give rise to side effects in certain sensitive subjects These 
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consist of nausea, dizziness, vomiting and orthostatic hypotension, but they are 
mostly dose dependent and temporary. 
The safety of bromocriptine has been proven in many studies (Vance et al. 1984). 
Teratogenic effects have not been observed neither in animal experiments nor 
in pregnancies originated during bromocriptine medication (Corenbium 1979, 
Turkalj et al. 1982, Krupp et al. 1984). 
Even when bromocriptine is commenced in a low dosage and slowly increased 
to therapeutic values, many patients are still unable to tolerate this drug. Its 
rather short halflife time necessitates frequent administration which is a dis­
advantage with regard to compliance. In some publications it is even suggested 
that severe side effects can occur particularly during the puerperium, but the 
value of these observations can be argued (Iffy et al. 1986, Katz et al. 1985, 
Shukla et al. 1985, Kemperman and Zwanikken 1987). With this in mind, however, 
it was justified to look for new dopamine agonists with the same or better prolactin 
reducing effect, but with less side effects and with a need of less frequent 
administrations to improve compliance. In view of the side effects of bromo­
criptine, which for the largest part are due to its alkaloid molecular structure, 
one has aimed for dopamine agonists which are not derived from the ergot-
alkaloids. In the following chapters the results of studies regarding efficacy, 
tolerance and safety of new dopamine agonists are being discussed. 
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CHAPTER 2 
PROLACTIN SUPPRESSANT EFFECT OF CQP 201-403, 
A NEW DOPAMINE AGONIST, 
IN HYPERPROLACTINAEMIC WOMEN 
P.F.M. van der Heijden, R. Rolland, J. Brownell 
Gynaecologie Endocrinology 1987,1 93 
ABSTRACT 
To meet the need for a dopamine agonist compound which would offer longer action and improved 
tolerabihty, CQP 201-403 has been developed CQP is a propyl-ergolme which has shown specific 
and strong 24 hr prolactin suppression in healthy volunteers at oral doses of 0 01 mg and higher 
In the study 24 hyperprolactinaemic women were given once daily doses of 0 01 mg, 0 02 mg 
or 0 03 mg CQP 201-403, or placebo for 7 days in a double-blind study to assess the prolactin 
suppressant action and tolerabihty of the compound 
The results show dose dependent prolactin suppression following the initial CQP dose which was 
sustained in steady state, when a clear 24-hour action was seen Tolerabihty was good and no 
drug attributable changes in safety measures occurred On the basis of its facility to suppress prolactin 
at well tolerated once daily doses, CQP would offer an advantage over currently available drugs 
Long-term therapeutic studies in hyperprolactinaemia are therefore warranted 
INTRODUCTION 
Since the introduction of synthetic dopamine agonists such as bromocriptine 
(Parlodel®) in the early 1970's, these drugs have been used in a variety of diseases; 
for example, persistent hyperprolactinaemia (1), inhibition of puerperal lactation 
(2), acromegaly (3) and Parkinson's disease (4). Except for the indication of 
puerperal lactation inhibition, therapy is generally of long duration, since most 
of these diseases are permanent (5). 
The half-life of bromocriptine is relatively short, and, especially if higher doses 
are necessary, the drug has to be taken several times throughout the day (6). 
Although Parlodel11 is generally well tolerated, in some instances it gives rise 
to poor tolerance at the beginning of treatment or to persistent side-effects which 
demand that treatment be discontinued. Hence there is a need for new dopamine 
agonists with specific prolactin-lowering effects, with a longer half-life and if 
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possible with an improved adverse reaction profile. CQP 201-403 (figure 1) 
is a new 8-amino-ergoline which has an extremely potent prolactin-lowering 
effect in animals (7) and also in healthy human volunteers (8). The aim of 
the study reported here was to define the optimal once daily dosage of CQP 
201-403 and to assess safety and tolerance in hyperprolactinaemic female 
volunteers. 
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Figure 1. Structural formula of 8-amino-ergoline (CQP 201 -403). 
MATERIALS AND METHODS 
Selection of volunteers 
The study was conducted according to the Tokyo amendment of the Declaration 
of Helsinki (1975). After the protocol had been approved by the ethical committee 
of the university hospital, 24 women suffering from persistent hyperprolactinaemia 
(prolactin above 1200 mil /1) were invited to take part in the study. After receiving 
information concerning the trial, both by word of mouth and in written form, 
they all gave their signed consent to participate. Except for their hyperprolac­
tinaemia, they were healthy women aged between 18 and 50 years. In women 
using Parlodel11, the intake of this drug was stopped at least one month prior 
to the study. None of the women showed signs of a pituitary macroadenoma 
with extra-sellar extension. 
Study design 
The study was performed double-blind and placebo-controlled. The 24 patients 
were randomized and placed in one of three treatment groups receiving either 
0.01 mg, 0.02 mg or 0.03 mg of CQP. In each group two of the eight women 
received placebo. The results from the six placebo-treated women were grouped 
together for statistical comparison with six women who received the drug in 
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each group. The duration of the study was seven days. Each group started the 
intake of CQP 201-403 or placebo at 9.00 hours on day 1. During this day 
(the acute phase of the study) the women remained at the clinic for assessment 
of vital signs and tolerance. On days 2 through 6 the women continued to take 
the capsules at home once daily after breakfast. On day 7 they again stayed 
in the clinic for assessment as on day 1, and returning for final measurement 
of safety parameters at 9.00 hours on day 8. If side-effects occurred at any 
time other than during the stays at the clinic visits the primary investigator 
was available by telephone. The women were routinely contacted by telephone 
on days 3 and 5 for enquiry concerning tolerance. 
Protocol 
During the week preceding the start of the study and on day 8 (24 hours after 
the last capsule intake) the following parameters were measured: ECG; complete 
urinalysis; hematology, consisting of hemoglobine, haematocrit, white cell count 
with differential and platelets; and blood chemistry, including minerals, bicar­
bonate, calcium, phosphorus, urea, uric acid, creatinine, glucose, total proteins 
and albumen, total bilirubin, triglycerides, cholestrol, alkaline phosphatase, LDH, 
ASAT, ALAT and CPK. All these parameters were measured by standard 
laboratory techniques. 
Vital signs and hormone measurements 
On day one, 1 hour before drug intake, at drug intake and г, 1, 2, 6 and 
8 hours thereafter, pulse rate, blood pressure (supine and standing), body 
temperature, respiratory rate, and weight were measured. These measurements 
were repeated on day 7, with additional measurements 10, 12, 23 and 24 hours 
after intake of the last capsule. Blood samples for assay of prolactin concentration 
were taken on day 1 immediately before capsule intake and 1, 2, 4, 6 and 
8 hours thereafter. On day 7 blood was sampled at the same time intervals. 
In addition, samples were taken 1 hour before and 10, 12, 23 and 24 hours 
after intake. Serum prolactin concentrations were measured by a specific 
homologous DASP radioimmunoassay (9) with an intra-assay coefficient of 
variation of 6.3%. In addition to prolactin, FSH, LH, TSH, growth hormone 
and Cortisol were measured by specific radioimmunoassay in the samples, 
employing a methodology previously described (9). 
Analysis of results 
All data collected were analyzed by means of descriptive statistics. According 
to treatment group mean, median standard deviation and minimum and maximum 
22 
values for each parameter were calculated. The six placebo-treated patients were 
pooled across cohorts for comparison with the six drug-treated women in each 
group. Prolactin values in the CQP treatment groups were compared with placebo 
values at individual time points using the Student t test for paired observations. 
RESULTS 
Prolactin 
In figure 2 (left-hand panel) the prolactin levels obtained on day 1 (acute phase) 
are shown. All three groups receiving CQP 201-403 show a clear prolactin-
lowering effect, which is most pronounced in the 0.03 mg treated group. On 
day 1 prolactin suppression in the 0.01 mg treated group was significantly different 
from the placebo-treated group from 2 hours after drug ingestion (P < 0.05). 
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Figure 2. Mean (±SEM) serum prolactin concentrations on day 1: acute phase (left-hand panel); 
and mean (±SEM) serum concentrations on day 7: steady state (right-hand panel). 
A similar pattern was seen in the 0.02 mg and 0.03 mg treated groups. At 
8 hours the prolactin suppressant effect in these latter two groups was significantly 
greater than that seen in the lowest dose group (P < 0.05). The steady state 
prolactin concentrations obtained on day 7 are shown in the right-hand panel 
of figure 2. A clear difference is seen in all CQP 201-403 treated groups compared 
with the placebo group, with the strongest effect following the two higher doses. 
Results of the Student t test for paired observations applied to the data from 
hours 0, 6, 12 and 24 on day 7 compared with hour 0 (pretreatment) on day 
1, show statistically significant prolactin reductions in all drug-treated groups 
(P < 0.05). 
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Vital signs 
Body tempei ature, body weight and respiratory rate on days 1 or 7 showed 
no change which could have been treatment-related (data are not shown). 
Figure 3 shows the changes in pulse rate in supine position and after 3 minutes 
standing, on day 1. The scatter within each group, especially in the upright 
values, is large (not shown); however, no systematic change in this parameter 
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Figure 3. Radial pulse in supine position expressed as changes from baseline (left-hand panel); 
and radial pulse in standing position expressed as changes from baseline (nght-hand panel). The 
data shown are mean values and 95% confidence limits of the three CQP 201-403 groups and 
the placebo group. 
could be found in relation to drug intake. A similar pattern was seen on day 
7 (data not shown). The few instances of transient pulse rate increases which 
were measured accompanied adverse reactions (see below). Figure 4 illustrates 
changes in blood pressure from baseline on day 1 in supine and standing positions. 
No marked changes were measured in any of the CQP 201-403 treatment groups 
on day 1. This pattern was again apparent during steady state on day 7 (data 
not shown). 
The interpretation of the ECGs taken before the study began and on day 8 
showed that all recordings were within normal limits, with one exception. One 
woman in the 0.02 mg CQP 201-403 treatment group showed a disturbed 
repolarisation of the left ventricular wall, a borderline anomaly which was present 
at baseline and on day 8. 
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Figure 4. Changes from baseline of systolic and diastolic blood pressure on day one. The data 
shown are mean values and 95% confidence limits of the three CQP 201-403 groups and the 
placebo group. 
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Laboratory safety parameters 
In isolated instances, some values appeared outside the normal range for the 
laboratory. However, for neither urinary nor hematology or blood chemistry 
measures could any value change be attributed to an action of CQP 201-403. 
Adverse reactions 
A summary of all adverse reactions is given in table 1, classified according 
to body system. The adverse reactions, typical of those observed following other 
dopaminomimetic drugs, were reported most often in the two highest drug dose 
groups. These reactions, predominantly consisting of dizziness and feeling of 
faintness, were most often recorded on day 1 between two and four hours after 
drug intake and were relieved by lying down. Although in some women adverse 
reactions reappeared on subsequent study days, their number and intensity 
diminished throughout the week, and in no case was study discontinuation 
necessary. 
Table 1. Number of patients with commonly reported adverse reactions during 8-day observation 
Adverse reaction Treatment 
per body system 
0.01 mg 0.02 mg 0.03mg placebo 
(n=6) (n=6) (n=6) (n=6) 
Central nervous system 
Dizziness, weakness, faintness 1 6 3 3 
Headache 4 
Gastrointestinal 
Nausea (vomiting) 1 (-) 3 (-) 2 (-) 
Respiratory 
Nasal stuffiness - - 2 -
Other hormonal parameters 
Figure 5 summarizes the changes from baseline (day 1, hour 0) on the serum 
concentrations of FSH, LH and TSH measured throughout day 1 and day 7. 
No alterations which could have been attributable to the intake of CQP 201-
403 occurred in any of these hormones. Figure 6 shows the changes from baseline 
(day 1, hour 0) of Cortisol; all groups show the expected daytime decrease of 
this hormone. Growth hormone values are presented in table 2. The isolated 
spikes occur equally in each group, including the placebo, and all other values 
are in the normal range. 
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Figure 5. Percentage changes in FSH, LH and TSH from baseline (left-hand panel: day 1, 
0; right-hand panel: day 7, hour 0) Results are expressed as mean ±SEM. 
hour 
Table 2. Growth hormone values <10 mU/1 and incidental spikes (>10 ml!/I) in the placebo 
group and the three CQP 201-403 treated groups on day 1 (acute state) and day 7 (steady state). 
state Group 0.01 mg Group 0.02 mg Group 0.03 mg Placebo 
acute steady acute steady acute steady acute steady 
Normal range 
« l O m U / l ) 
35 64 33 65 34 62 34 65 
Incidental spikes 
(>10mU/l) 
Total number 
of samples 
36 65 36 66 35 64 36 66 
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Figure 6. Percentage changes in Cortisol from baseline (left-hand panel: day 1, hour 0; right-hand 
panel: day 7, hour 0). Results are expressed as mean ±SEM. 
DISCUSSION 
The results of the study reported here allow the conclusion to be made that 
the new dopamine agonist, CQP 201-403, is a strong and long-acting prolactin 
supressant compound in patients with hyperprolactinaemia, as previously also 
demonstrated in healthy volunteers. The marked prolactin-lowering effect, which 
was apparent on the 1st day of treatment in all dose groups, was sustained 
at the 0.02 mg and 0.03 mg dose levels during steady state on day 7, when 
clear indication of a 24-hour action was seen. In these patients serum prolactin 
suppression reached statistical (P < 0.05) and clinical (values to the normal 
range) significance. This therapeutically relevant effect was accompanied by 
good drug tolerance, most side-effects being subjective accompaniments of 
transient postural hypotension. No clinically meaningful alterations in any of 
the physical, hematological or urine safety tests were seen. On the basis of its 
facility to suppress prolactin at well tolerated doses, CQP 201-403 would clearly 
offer an advance in the treatment of hyperprolactinaemia. Bromocriptine, the 
most extensively used compound available for this indication, is usually given 
at subclinical doses at the beginning of treatment until the adverse reaction 
profile improves. Doses must then be given several times daily to sustain 
suppression. CQP 201-403, on the other hand, with its 24-hour action, can be 
given once daily, and if taken at bedtime, such side-effects as appeared several 
hours after morning drug intake in the present study would be avoided. Further 
studies with CQP 201-403 are therefore warranted to assess its efficacy in 
hyperprolactinaemic patients treated for longer periods. 
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CHAPTER 3 
ENDOCRINE EFFECTS OF CV 205-502, A NEW 
DOPAMINE AGONIST, IN 
HYPERPROLACTINAEMIC WOMEN 
P.F.M. van der Heijden, R. Rolland, C M C Thomas, J. Brownell 
Gynaecologie Endocrinology 1988,2 233 
ABSTRACT 
CV 205-502 (CV) is a potent dopaminergic compound which exerts a strong and sustained suppression 
of prolactin secretion in healthy volunteers 
In a prospective double-blind, randomized placebo-controlled trial, 12 hyperprolactinaemic women 
(> 2000 mU /1), were divided into two groups of 6 women each, treated for 4 weeks Combined 
pituitary challenge tests (GnRH, TRH, CRH and GHRH) were performed before and after treatment 
The 6 CV 205-502-treated women (0 05 mg daily) showed approximately a 64% decrease of their 
initial prolactin serum concentrations after 4 weeks of capsule intake Placebo-treated women showed 
no change in their prolactin serum level After TRH administration, a blunted prolactin response 
was present in all women before treatment After CV treatment a trend towards normalization 
of the prolactin response to TRH was seen, whereas the response pattern in the placebo group 
remained unaltered 
The responses of GH, TSH, LH, and ACTH to their releasing hormones and Cortisol showed no 
significant changes after administration FSH, however, showed a significant decrease in response 
to LHRH, which could be explained by an increase in estradiol (E;) as ovanan function normalized 
in CV 205-502-treated women 
In conclusion, CV 205-502 shows strong dopamine agonistic properties in hyperprolactinaemic 
women treated with 0 05 mg CV daily The profile of this new quinohne compound, as judged 
from the pituitary challenge tests, does not differ from that of dopamine agonists of the ergolme 
type 
INTRODUCTION 
Ergot alkaloids and their synthetic derivatives are prescribed in a variety of 
diseases. In treating hyperprolactinaemia, acromegaly and Parkinsonism (I), these 
compounds, like bromocriptine (ParlodelR), have proved to be very successful. 
CV 205-502, an octahydrobenzo-[g]-quinoline, is a unique dopamine agonist 
compound (figure 1 ), which as well as effecting potent and sustained suppression 
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Figure 1. CV 205-502: octahydrobcnzo[g]quinoline 
of prolactin secretion, is well tolerated, with only a low incidence of adverse 
reactions in healthy volunteers and in patients (2,3). In order to investigate further 
the prolactin-lowering efficacy of CV 205-502 in hyperprolactinaemic women 
and to assess the effect of hypothalamic releasing hormones on the pituitary-
thyroid, -adrenal and -gonadal axes and on growth hormone previous to and 
during steady-state CV 205-502 treatment, pituitary challenge tests were per­
formed. 
MATERIALS AND METHODS 
Selection of patients 
The study was conducted according to the Tokyo amendment of the Declarati­
on of Helsinki (1975). After its design had been approved by the ethical committee 
of the University Hospital, 12 women who were suffering from hyperprolac-
tinaemia (prolactin persistently above 2000 mU /1) were invited to take part 
in it. Having received information concerning the trial, all gave their written 
consent. 
Except for their hyperprolactinaemia, they were healthy women aged between 
24 and 44 years (mean age 35.1 ± 6.4 (SD) years). The Quetelet index ([weight/ 
height^xlO5) was within the normal range for the different age groups (4). Six 
women were suffering from secondary amenorrhoea. The other 6 had more 
or less regular cycles before selection. Of these, 3 used bromocriptine which 
was stopped at least 1 month prior to the study. Only when it had been confirmed 
that in the absence of bromocriptine their serum prolactin levels had increased 
to above 2000 mU /1, were these women admitted to the study. The remaining 
3 women had more or less regular cycles despite their hyperprolactinaemia. 
Since in 3 women bromocriptine was stopped rather close to commencement 
of the study, 6 women in total had menstrual episodes in the period immediately 
prior to the study. As judged from their menstrual history, 3 were in the follicular 
phase of the cycle and the remaining 3 premenstrual on the day of the 1st 
challenge test. None of the women showed signs of a pituitary macroadenoma 
by routine tomography or CT-scan of the pituitary fossa. 
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Hormone assays 
Serum concentrations of LH, FSH, and TSH were measured with specific double 
antibody solid-phase based radioimmunoassays developed in our laboratory and 
described previously (5,6) Prolactin and growth hormone measurements were 
performed with the Spectna RIAs purchased from Farmos Diagnostica (Turku, 
Finland) Cortisol was assayed by applying the coated tube RIA available from 
Baxter Travenol, Clinical Assays Ine (Boston, Massachusetts, USA) E2 and Ρ 
were measured with previously desenbed in-house RIAs (7) ACTH was de­
termined by use of an immunoradiometnc assay (IRMA) purchased from 
Eurodiagnostics BV (Apeldoorn, The Netherlands) Assay characteristics are 
shown in table 1. The assay sensitivities depicted in table 1 are defined by the 
dose reading at zero-binding minus 2 χ the standard error (SE) in the case 
of RIA, whereas the IRMA applied the dose reading at zero-binding plus 2 
χ SE Assay precision was calculated from means of duplicate measurements 
of serum pools (8), and is expressed in percent coefficient of variation (CV) 
of both within (CVw) and between (CVb) assay variability 
Table I Standard dose range, sensitivity and precision of the hormone assays 
Hormone 
LH 
FSH 
TSH 
PRL 
GH 
Cor 
ACTH 
E2 
Ρ 
Umlage 
lU/l 
IU/1 
mIU/1 
mIU/1 
mIU/1 
nmol/1 
ng/1 
fmol /tube 
fmol /tube 
Standard 
dose range 
4 0 250 
16-100 
10 65 
50 5000 
10 100 
30 1700 
20-1000 
10 1500 
50 3200 
Sensitivity 
15 
0 35 
0 70 
30 
0 20 
10 
8 0 
5 0 
25 
%CVW 
8 3 
81 
7 0 
5 6 
41 
32 
3 2 
4 3 
41 
Precision 
%cv b 
125 
121 
8 9 
81 
8 8 
6 3 
7 0 
7 9 
91 
η 
99 
62 
48 
57 
30 
92 
12 
78 
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The specificity of both RIA and IRMA in terms of percent cross reactivities 
was tested by adding various amounts of relevant peptide or steroid hormones 
to the different assays and is calculated (9) In the case of Prl, LH, FSH and 
TSH the cross reactivity of all peptide hormones tested was negligible, except 
for hCG (human Chorionic Gonadotrophin) which showed a significant cross-
reaction of 100% in the LH RIA The Cortisol RIA gave a substantial cross-
reaction only with prednisolone (73%) and 6-methylprednisolone (18%), whereas 
the hGH (human Growth Hormone) assay revealed 100% cross-reactivity with 
hPL (human Placental Lactogen) In the ACTH IRMA the ACTH fragments 
1-24, 1-32, and 18-39 did not interfere The Ρ RIA showed some cross-reactivity 
with 11-deoxycorticosterone (3 8%), whereas Е
г
 cross-reacted only with Ej for 
1 0% All other steroids tested for both Ρ and Ej assays showed cross reactions 
of less than 1% 
32 
Statistical procedure 
The results of the hormone measurements prior to therapy (6 women in each 
group) were compared with those obtained during treatment either with CV 
205-502 (6 women) or placebo (6 women) to see whether significant changes 
had taken place. Secondly the results obtained during CV 205-502 treatment 
were compared with those found for women taking placebo. For both purposes 
the unpaired and paired Student t tests were used and a ρ < 0.05 was considered 
as a significant change. To compare the value of a given hormone at time 0 
with the peak value, the Wilcoxon signed rank test was used. For the sake 
of presentation the data of each hormone within the different groups are shown 
as mean + 1 χ SEM either in graph or table form. 
Study design 
The study was performed double-blind and placebo-controlled. The 12 patients 
were randomized and treated in 2 groups of 6 patients each. CV 205-502 (0.05 
mg) or a placebo was given once daily in capsules of identical appearance. 
Before treatment was started, a combined anterior pituitary function test was 
performed. The 4 hypothalamic releasing hormones were given intravenously 
to establish response patterns while the women were hyperprolactinaemic. One 
month later the challenge tests were repeated to obtain the response patterns 
while the patients were under CV 205-502 or placebo treatment. 
The following releasing hormones were administered in a fixed sequence GnRH 
(Gonadotropin hormone-Releasing Hormone, Ayerst lab., New York), 100 μg 
dissolved in 5 ml; TRH (Thyrotropin-Releasing Hormone, Roche Ltd, Holland), 
200 μg dissolved in 2 ml; CRH (rat Corticotropin-Releasing Hormone, Bachern 
AG, Switzerland), 100 ug dissolved in 1 ml; GHRH (Growth Hormone-Releasing 
Hormone, factor 1-4, Bachern Ltd, Torrance California, USA), 100 μg dissolved 
in 1 ml. 
All challenge tests started at 9.00 hours after an overnight fast and the patients 
remained in supine position during the first 90 minutes of the test. The releasing 
hormones (total volume 9 cc) were injected slowly intravenously within a total 
period of 3 minutes. Before injection 2 blood samples were taken, at -15 and 
0 minutes (baseline). Thereafter samples were taken at frequent intervals for 
3 hours: 5, 10, 20, 30, 60, 120 and 180 minutes, after the commencement of 
the injection. They were placed immediately on crushed ice and remained at 
4 0 C until centrifugation had taken place. All serum samples were frozen and 
stored at -20oC until assayed. For a particular hormone, all samples from one 
patient were measured within the same assay run. In all samples Prolactin (Prl), 
FSH (Follicle Stimulating Hormone), LH (Luteinizing Hormone), TSH (Thyroid 
Stimulating Hormone), ACTH (Adrenal Corticotropic Hormone), GH (Growth 
Hormone) and Cortisol were measured. Estradiol- Π β (OEj) and progesterone 
(Ρ) were determined only in the baseline samples in the pooled -15 and 0 minute 
samples. 
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The next day all women started to take either CV 205-502 (0.05 mg) or the 
placebo at bedtime and they continued this treatment for 4 weeks. 
Possible side-effects were recorded, as were safety measurements (blood chem­
istry, hematology, urine analysis and ECG). However, this was not the objective 
of the study and these data will be reported elsewhere as part of a larger study 
on efficacy, safety and tolerance of CV 205-502 treatment. 
After 4 weeks of capsule intake the challenge tests were repeated in exactly 
the same manner as described above and the collected serum samples were 
stored until assayed. 
RESULTS 
Prolactin (figure 2) 
Before the challenge tests all women showed clearly elevated prolactin levels, 
with a mean of 3500 mU/1 (± 566) and 3100 mU/1 (±463) in the placebo 
and СV 205-502 groups, respectively. After TRH administration prolactin showed 
rather blunted or nearly absent response patterns, with small increases and peak 
levels at 30 minutes, followed by a slow decrease back to baseline. After 4 
weeks of drug intake the placebo group showed identical basal prolactin levels 
and the response to TRH was also unaltered. However, the women treated with 
CV 205-502 had a significant decrease in basal prolactin, to a mean serum 
prolactin level of 1266 mU/1 (± 335.1 mU/1, ρ ^ 0.05). After the TRH 
administration prolactin increased to a maximum of 2461 mU/1 at 30 minutes 
(p ^ 0.01 as compared to time 0). This was followed by a gradual decrease 
back to baseline. The response curve in patients taking С V 205-502 is significantly 
different both from the curves seen previous to drug intake from those in patients 
having placebo treatment when the areas under the curve are compared (ρ ^ 
0.02). 
Pituitary gonadal axis 
One woman in the group treated with CV 205-502 appeared to have a sponta­
neous ovulation very close to the basal challenge test (LH 49 IU/1 and Ej 910 
pmol/1) and has therefore not been included in the presentation of the FSH 
and LH data. Another woman in the same group was in the luteal phase of 
the cycle (progesterone 51 nmol/1), whereas all other women in both groups 
had progesterone levels below 6.3 nmol /1 and estradiol levels below 295 pmol / 
1, indicative of anovulation. After 4 weeks of treatment 3 of the of 6 women 
in the CV 205-502 group were in the luteal phase (progesterone 23, 39 and 
83 nmol /1, respectively), whereas none of the 6 in the placebo group had showed 
progesterone levels above 4.8 nmol/1 and all estradiol levels were below 200 
pmol /1. Thus anovulation persisted during placebo treatment, whereas 3 out 
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Figure 2. Mean ± SEM serum prolactin levels (mU /L) in 12 hyperprolactinaemic women previous 
to (upper panel) and after 4 weeks of CV 205-502 versus placebo treatment (lower panel) 
Open squares = women treated with CV 205-502 Closed squares = women treated with placebo. 
of 6 women in the CV 205-502 treated group had ovulated. The FSH and 
LH responses are shown in figure 3. With regard to FSH, there was a marked 
difference between the women treated with CV 205-502 and those treated with 
placebo, especially during treatment. The LH responses in the basal experiments 
were nearly identical, as were the responses during treatment. The mean maximum 
LH response during treatment with CV 205-502 seems lower if compared to 
the basal experiment, but this difference is not statistically significant. 
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Figure 3 Mean ± SEM serum FSH (U /L, left side) and LH (U /L, right side) in 12 hyperprolactinae-
mic women Previous to (upper panel) and after 4 weeks of CV 205-502 versus placebo treatment 
(lower panel) 
Open squares = women treated with CV 205-502 Closed squares = women treated with placebo 
Growth hormone (figure 4) 
Basal growth hormone levels were normal in both groups (t= 0:5.4 ± 2.8 versus 
2.4 ± 1.3 mU/1), (p = 0.4). After GHRH administration GH increased rapidly 
in both groups to a maximum of 30.0 versus 29.6 mU /1 at 30 minutes, then 
decreased thereafter to basal values at 180 minutes. During treatment women 
receiving placebo capsules showed the same response pattern, although the mean 
peak value at 30 minutes was lower (23.5±8.3 mU/1). This difference is not 
statistically significant. However, women treated with CV 205-502 showed a 
more rapid response to GHRH, with a mean higher maximum level at 30 minutes 
(36.7±8.7 mU /1). This difference is also not significant (p = 0.3). At 180 minutes 
GH was back within the normal range in both groups. 
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Figure 4 Mean ± SEM serum growth hormone levels (mU/L) in 12 hyperprolactmaemic women 
previous lo (upper panel) and after 4 weeks of CV 205-502 versus placebo treatment (lower panel) 
Open squares = women treated with CV 205-502 Closed squares = women treated with placebo 
Thyroid stimulating hormone 
The TSH responses to TRH are shown in figure 5. The response patterns before 
and during CV 205-502 or placebo treatment are practically identical, indicating 
no effect of CV 205-502 on the pituitary capacity to release TSH 
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Figure 5. Mean ± SEM serum TSH (mU/L) in 12 hyperprolactinaemic women previous to (upper 
panel) and after 4 weeks of CV 205-502 versus placebo treatment (lower panel). 
Open squares = women treated with CV 205-502 Closed squares = women treated with placebo. 
Pituitary-adrenal axis 
Figures 6 and 7 show the mean values (±SEM) of ACTH and Cortisol in both 
groups during the basal and treatment experiments. The wide scatter of ACTH 
values in the CV 205-502 group previous to treatment is striking, but the groups 
are not significantly different at any time point. During capsule intake the 
responses in the 2 groups were practically identical, indicating no effect of CV 
205-502 on the pituitary capacity to release ACTH in response to CRH. During 
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Figure 6. Mean ± SEM serum ACTH (ng/L) in 12 hyperprolactinaemic women previous to (upper 
panel) and after 4 weeks of CV 205-502 versus placebo treatment (lower panel). 
Open squares = women treated with CV 205-502. Closed squares = women treated with placebo. 
both the basal experiment and placebo or CV 205-502 treatment there were 
no changes in the response curves of Cortisol, which remained nearly identical, 
indicating no effect of CV 205-502 on Cortisol. The tendency to lower Cortisol 
values at the end of the experiments (t= 180 minutes versus t=0) is easily explained 
by the known decrease of Cortisol during the day. 
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Figure 7 Mean ± SEM serum Cortisol (umol/L) in 12 hyperprolactinaemic women previous to 
(upper panel) and after 4 weeks of CV 205-502 versus placebo treatment (lower panel). 
Open squares = women treated with CV 205-502 Closed squares = women treated with placebo. 
DISCUSSION 
The novel dopamine agonist CV 205-502 (octahydrobenzo[g]quinoline) has 
previously been shown to exert an excellent prolactin lowering effect with good 
tolerance in normoprolactinaemic volunteers and in hyperprolactinaemic patients 
(2,3). This is also true for dopamine agonists of the ergoline type, such as 
bromocriptine, although such compounds are poorly tolerated by normoprolac­
tinaemic and even some hyperprolactinaemic subjects (1). Futhermore, CV 205-
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502 has an extended biological half-life as compared to bromocriptine; con-
sequently, once-daily administration is sufficient to ensure effective prolactin 
suppression over the next 24-hour period (2). In this study the strong prolactin-
lowering effect was again demonstrated in hyperprolactinaemic women, as the 
six women receiving CV 205-502 showed a significant decrease in serum 
prolactin, from 3100 mU/1 (±463 mU/1) to 1266 mU/1 (±335 mU/1), after 
4 weeks' intake of 0.05 mg daily, in contrast to the placebo treated group. 
Since dose-finding studies with this compound in hyperprolactinaemic women 
have not yet been reported, it is no surprise that not all the women treated 
with it had normalized their serum prolactin levels by 4 weeks, as the initial 
dose might not have been adequate. As the drug has very few side-effects and 
is very well tolerated, a higher starting dose seems justified. 
The main reason for performing this study was to evaluate the effects of combined 
challenge tests with hypothalamic releasing hormones in hyperprolactinaemic 
women both while receiving no treatment and while being treated with CV 
205-502 or placebo, to look into the effects of this new dopamine agonistic 
compound on pituitary function. As in many previous studies (10), we also 
combined several releasing hormones. This is justified by the fact that no synergism 
or inhibition in the hormonal response to these releasing hormones has been 
shown whether they are presented combined or when each releasing hormone 
has been given separately (11). However, some reports have suggested that in 
combined challenge tests the TSH response to TRH might be enhanced (12). 
Even if this is so, it does not influence the validity of the present study, as, 
if a difference in the TSH response to TRH had appeared during CV 205-
502 treatment, it could have been attributed only to either the normalization 
of prolactin or a direct effect of the drug, since results previous to and during 
drug treatment and those of the placebo group were compared. It can therefore 
be concluded that administration of CV 205-502 does not influence the pituitary 
capacity to release TSH in response to TRH. This is in agreement with previous 
studies where TSH was measured in hyperprolactinaemic women before and 
during bromocriptine treatment (12,13). 
The results of the present study confirm previous findings that CV 205-502 
shows strong prolactin suppressant properties in hyperprolactinaemic women 
(3), such as those seen in normoprolactinaemic male volunteers (2) and also 
confirm the finding that hyperprolactinaemic women show a blunted or even 
absent prolactin response to TRH (14). In healthy normoprolactinaemic women, 
serum prolactin alsv. increases by 4-5 times in response to a challenge by TRH 
(15). After administration of CV 205-502 to the male volunteers this prolactin 
response appeared blunted and the explanation was thought to be the blocking 
effect of the compound at the level of the lactotrophs (16). This differs from 
the findings in the present study, which clearly show a trend towards normalization 
of the prolactin response to TRH in women taking CV 205-502 and furthermore 
agree with findings in postpartum women treated with bromocriptine for the 
purpose of inhibition of lactation. In the latter women a trend towards nor-
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malization is seen when they are given TRH within 3 weeks of delivery, during 
the course of bromocriptine treatment (17) In vitro studies by Pasteeis et al 
(18) also showed that although spontaneous prolactin release by normal pituitary 
tissue is inhibited when dopamine agonists are added to the culture medium, 
addition of TRH gives rise to an increased release of prolactin It is therefore 
suggested that although dopamine agonists block the release of the hormone 
at the level of the lactotrophs, these cells remain capable of responding to TRH 
for at least 3-4 weeks Since the lactotroph response is the inability to release 
prolactin, and perhaps also the synthesis of new hormone, it may be that after 
a longer period of treatment the cells become unresponsive to TRH since they 
have become completely depleted of prolactin 
Infusion of dopamine inhibits the release of growth hormone release inhibiting 
factor (SRIF) (19) From a theoretical point of view one could assume that 
this would give rise to an exaggerated GH response to GHRH This is also 
demonstrated in the present study, although the increase in response is rather 
small It is also known that dopamine itself inhibits the GH release at the pituitary 
level (20) The observed ch ges in the GH response to GHRH in the present 
study might therefore be exph Jed by competition between these two mechanisms 
It should be stressed that although these changes do occur, basal growth hormone 
levels remained within normal limits in women treated with CV 205-502 If 
treatment is continued beyond several weeks, the GH response to GHRH also 
normalizes (21) 
Numerous studies have shown that as scruni prolactin normalizes in hyperprolacti-
naemic women treated with dopamine agonists, so does the function of the ovary 
with restored fertility (22) Although recording ovarian function was not the 
aim of this study, a trend towards normalization was noted in the six women 
who were given CV 205-502 Of these, 3 had ovulated within 4 weeks of treatment, 
as compared to none in the placebo group Indeed an extended study in 41 
hyperprolactmaemic women has shown that within 3 months of initiation of 
CV 205-502 treatment 19 out of 25 previously amenorrhoeic women re-initiated 
their cycles (see chapter 4) The exaggerated FSH response to GnRH prior to 
treatment in all women and persisting in placebo-treated women is well in 
agreement with previous findings in hyperprolactmaemic women (23) Such a 
response pattern is also seen in amenorrrhoeic-normoprolactinaemic women with 
impaired pulsatile release of GnRH (24) and suggests that their failure to maintain 
normal ovulatory cycles while being hyperprolactmaemic is due to a defect at 
the hypothalamic level Surgical removal of prolactin-producing pituitary tumors 
also restores ovarian function and this suggests that the hypogonadism observed 
in hyperprolactmaemic women is due to a short-loop feedback of prolactin itself 
at the level of the hypothalamus The hypothalamic-pituitary-adrenal axis was 
not influenced by the intake of CV 205-502 This is in agreement with previous 
reports showing no change in this axis in healthy volunteers treated with CV 
205-502 (16) and in hyperprolactmaemic women with or without other dopamine 
agonist therapy (25) 
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It is concluded that the profile of CV 205-502 as judged from these challenge 
studies is not different from that of other dopamine agonistic drugs such as 
bromocnptine, despite the non-ergot structure of the drug Since the drug is 
well tolerated and once daily administration at bedtime is sufficient to maintain 
adequate prolactin suppression over a 24-hour penod (26) it is suggested that 
this compound may become a welcome alternative to the dopamine agonistic 
drugs currently available 
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CHAPTER 4 
THE EFFECTIVENESS, SAFETY AND TOLERABILITY 
OF CV 205-502 IN HYPERPROLACTINAEMIC WOMEN: 
A 12-month study 
P.F.M. van der Heijden, R.E. Lappöhn, R.S. Corbey, W.B.K.M.V. de Goeij, 
J. Brownell and R. Rolland 
Fertility and Sterility 1989,52-574 
ABSTRACT 
Forty-one hyperprolactinaemic women (prolactin (PRL) > 2000 mil /L) were treated between 12 
weeks and 52 weeks with the new nonergot, long-acting dopamine agonist octahydrobenzo[g]quinoline 
(CV 205-502) The treatment resulted in normalization of PRL secretion in 11% of the women 
at a once-daily dose of ^0 100 mg All women responded with a significant decrease in serum 
PRL Menstrual function normalized in all women except 1, whereas galactorrhoea disappeared 
in all but 2 patients During the observation penod, four pregnancies were recorded with an additional 
three in the immediate post treatment period Until now four healthy children have been born 
Regarding tolerabihty, women with fair or poor responses to bromocriptine (Parlodel®) in the past, 
tolerated CV 205-502 better Two women with no PRL decrease while on Parlodel®, responded 
with a decrease while on CV 205-502 All safety parameters remained normal while on treatment, 
and no significant changes were observed in blood pressure (supine and standing), pulse rate, or 
electrocardiogram (ECG) recordings CV 205-502 therefore seems to be a valuable new compound 
in the management of patients with hyperprolactinaemia 
INTRODUCTION 
Dopamine agonists have become the treatment of choice in hyperprolactinaemia 
and the inhibition of puerperal lactation and are also widely used in the indications 
of acromegaly and Parkinsonism (1). Bromocriptine (Parlodel11; Sandoz Ltd., 
Basle, Switzerland) is very effective in the suppression of serum prolactin (PRL), 
but may in some patients give rise to side effects like nausea, gastric upset, 
peripheral vasospasm, and orthostatic hypotension, especially at initiation of 
therapy. Due to its relatively short duration of action, it is recommended to 
take the drug two or more times daily to ensure normoprolactinaemia (2). CV 
205-502 (octahydrobenzo[g]quinoline) is a new PRI^suppressant drug (3). It 
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is the first nonergot dopamine agonist designed as a specific Dj receptor agonist 
and should, therefore, have a profile with less dopaminergic side effects because 
these depend more on D, receptors (4). Both in animal studies and in nor-
moprolactinaemic human volunteers and hyperprolactinaemic patients (5-8), CV 
205-502 has shown a strong PRL-lowering effect at once-daily administration 
(5). In dosages giving PRL suppression of 58% to 70% the drug was well tolerated, 
although in higher dosages, side effects like sleepiness and headache have occurred 
(6-8). No clinically relevant changes were observed in laboratory blood and 
urine tests, electrocardiograms (ECG), or physical examinations. Due to this 
promising profile of CV 205-502, it was decided to test the PRL lowering capacity 
in hyperprolactinaemic women, and the two following objectives were formulated 
a: to ascertain the dosage at which CV 205-502 exerts a clinically relevant 
PRL suppressant effect in hyperprolactinaemic patients, and b: to assess at regular 
intervals throughout a 12-month period the safety and tolerability of the drug. 
MATERIALS AND METHODS 
The study was conducted according to the Tokyo amendment of the Declaration 
of Helsinki. After approval by the hospital ethical committee, all patients gave 
their written, informed consent to participate. Forty-one women suffering from 
hyperprolactinaemia, with serum PRL levels persistently >2000 mU /1 (normal, 
< 800 mU /1, 36 mU /L = 1 ng /ml) on at least two occasions during the month 
preceding the study, agreed to participate. Except for their hyperprolactinaemia, 
they were all healthy women between 18 and 49 years of age. By routine 
radiography or computerized tomographic (CT) scanning of the pituitary fossa, 
none of them had signs of a macroadenoma. All women agreed to participate 
for a 12-week period unless side effects required discontinuation of the drug. 
Those who wanted to continue were allowed to do so for a treatment period 
of 52 weeks. Of these 41 women, 5 had spontaneous menstrual periods despite 
their hyperprolactinaemia. Twenty-five women had secondary amenorrhoea (> 6 
months) and 11 oligomenorrhoea (6 weeks to 6 months). Twenty-five of the 
41 women were suffering from galactorrhea. Twenty women were involuntarily 
infertile and 11 of them wanted to become pregnant during the study once 
their cycle had normalized and at least 3 consecutive menses had been monitored. 
During the first 4 weeks the study was conducted as double-blind, and the 
participating women were randomly assigned to receive either placebo or CV 
205-502 at a dose of 0.05 mg once daily. After 4 weeks the code was broken, 
and the placebo treated patients were also started on 0.05 mg CV 205-502. 
In the drug treated group, the daily dose of CV 205-502 was increased after 
4 weeks by 0.025 mg for the next 4 weeks if the PRL suppressant effect of 
CV 205-502 was judged insufficient (a PRL decrease of < 50% as compared 
with the previous value). If PRL again showed inadequate suppression, a further 
increase of the dosage was advised in monthly steps of 0.025 mg to a maximum 
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of 0.150 mg. In case of poor tolerance the dosage could also be decreased 
by 0.025 mg /d. The women who started on placebo followed the same sequence 
of possible drug increase/decrease, except that they started intake of CV 205-
502 four weeks later. 
The medication sets were supplied according to a computer-generated randomi-
zation list providing for code number assignment by blocks of four to ensure 
that approximately one-half of the patients received placebo treatment for the 
first 4 weeks. The capsules of active drug and placebo were of identical appearance 
and were both supplied in blister packets, each packet containing 28 capsules. 
All capsules were taken once daily at bedtime with a little snack throughout 
the study. 
Before therapy a physical examination and extensive blood and urine analyses 
were all normal. All pretreatment ECG recordings were also clinically normal. 
All these items were repeated throughout the study at 4-week intervals. PRL, 
body weight, blood pressure and pulse rate (supine and standing) were also 
recorded before the study, at 2-week intervals during the first 12 weeks of the 
study and thereafter every 4 weeks. At each visit the women were examined 
for the presence of galactorrhoea and questioned regarding the regulanty of 
the cycle and the occurrence of adverse reactions. 
Pretreatment findings in the two groups are shown in table 1. From this table 
it can be concluded that the randomization was successful. Most of the 
participating women had been treated with Parlodel® in the past (active drug 
group 20, placebo group 18). Regarding tolerability, 17 of these women had 
Table 1 Anamnestic and descriptive data of patients starting with CV 205-502a or placebo11 
Item 
No of women 
Age (y) I 6 ± 1 54 
Height (cm) 
Weight (kg) 
Panty 
multiparae 
nulliparae 
Galactorrhoea 
Infertility1 
Amenorrhoea'1 
Ohgomenorrhoea' 
Previous Parlodel® use 
"CV 205-502, octahydrobenzo[g]quinoline 
bExpressed as mean ± standard error of the mean or No of women (n) 
cMore than 1 y 
dMore than 6 mo 
eMore than 6 wk to < 6 mo 
CV group 
21 
32 3±1 33 
167 0 ± 127 
644 ± 18 
12 
9 
12 
10 
11 
6 
20 
Placebo group 
20 
166 1 ± 1 83 
676 ± 2 0 
11 
9 
12 
10 
14 
5 
18 
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responded favorably to Parlodel®, 12 women showed a fair response, and 9 
poor Twenty-eight women showed a good PRL lowering response to Parlodel®, 
and 8 a fair response, whereas 2 did not respond at all The responses good, 
fair, and poor were defined as follows good - the tolerated dose led to 
normalization of serum PRL, fair - the tolerated dose led to >50% decrease 
in scrum PRL, but no normalization was achieved, and poor - the maximal 
tolerated dose led to <50% decrease in serum PRL 
After 12 weeks of treatment, 11 of the 41 women discontinued the intake of 
CV 205-502 for personal reasons, and none of them stopped due to intolerabihty 
of the drug Therefore, 30 women continued intake of CV 205-502 beyond 
12 weeks Of these women, 14 came from the group that started with placebo 
instead of С V 205-502 for the first 4 weeks 
PRL was measured by use of the Spectna radioimmunoassay (RIA), purchased 
from Farmos Diagnostica (Turku, Finland) The sensitivity of this assay is 30 
mU /1, with an intra-assay and interassaycoefficient of variation of 5 6% and 
8 1%, respectively The upper limit of normal in menstruating women is 800 
mU /L All other laboratory measurements (blood hematology, chemistry and 
urine) were performed applying specific and sensitive standard laboratory 
procedures All results are expressed as geometric mean values ± standard error 
of the mean (SEM) and Student t test for paired observations was used for 
calculations of differences between mean values 
RESULTS 
Prolactin 
In table 2 an overview is given of the changes in serum PRL levels in all women 
during the active treatment phase with CV 205-502 Because at the start of 
capsule intake 20 women took placebo capsules for 4 weeks, the duration of 
treatment with active drug in this group is 4 weeks shorter (maximum duration 
48 weeks) Mean PRL concentrations decreased from 3526 + 416 to 784 + 
125 mU/1 at 12 weeks in the group started on CV 205-502 and from 3175 
± 378 to 688 ± 144 mU /1 in women started on placebo 
At this time 5 women discontinued treatment, 3 of whom had normalized their 
serum PRL m the CV 205-502 starting group At 8 weeks of active treatment 
6 women in the placebo starting group discontinued CV 205-502 use, 5 of 
whom had already normalized their PRL serum concentrations Twenty-four 
women were treated for 52 weeks, whereas 6 women discontinued treatment 
between 12 and 52 weeks Of these 6 women, 4 became pregnant with normal 
PRL levels at the time of conception, and 2 women discontinued treatment 
for other reasons with normal PRL serum concentrations at the time of 
discontinuation At 52 weeks, only 3 women had not normalized their serum 
PRL levels (2100, 1000 and 990 mU/1, respectively) This means that the 
percentage of women in the group under treatment rather resistant to CV 205-
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Tabic 2 Serum prolactin levels (mU /1) in the CV 205-502 group (CV) and the placebo-started 
group (Placebo /CV) throughout the study period 
group 
CV 
n" 
Mean 
SfcM 
Minimum 
Maximum 
% decline 
PLACEBO/CV 
n' 
Mean 
SEM 
Minimum 
Maximum 
% decline 
group 
CV 
n* 
Mean 
SEM 
Minimum 
Maximum 
% decline 
PLACEBO/CV 
nd 
Mean 
SEM 
Minimum 
Maximum 
% decline 
0 
21 
3526 
416 
990 
9260 
0 
20 
3175 
378 
1300 
6400 
0 
5 
15 
916 
167 
220 
2500 
74 
12 
921 
200 
100 
2400 
71 
05 
20 
1209 
215 
100 
3200 
66 
20 
3070 
361 
1200 
6600 
4 
6 
15 
737 
123 
190 
1900 
79 
13 
774 
186 
100 
2100 
76 
1 
21 
1317 
234 
100 
4200 
63 
20 
3130 
391 
610 
6800 
2 
7 
13 
786 
168 
270 
2500 
78 
13 
642 
120 
100 
1500 
80 
Month 
15 
21 
1047 
179 
100 
3100 
70 
20 
1043 
213 
100 
4200 
67 
Month 
8 
11 
813 
205 
270 
2700 
77 
13 
558 
145 
100 
2000 
82 
2 
21 
1033 
203 
100 
4000 
71 
20 
970 
212 
100 
3900 
69 
9 
11 
929 
208 
280 
2400 
76 
7 
771 
247 
100 
2100 
76 
25 
20 
919 
161 
100 
2600 
74 
19 
819 
165 
100 
2800 
74 
10 
12 
523 
87 
100 
1100 
85 
10 
711 
199 
100 
2000 
78 
3 
21 
784 
125 
100 
2200 
78 
19 
688 
144 
100 
2400 
78 
11 
13 
767 
196 
150 
2900 
78 
12 
596 
129 
100 
1700 
81 
4 
16 
855 
244 
100 
4100 
76 
14 
985 
239 
100 
2800 
69 
12 
12 
615 
156 
230 
2100 
83 
11 
558 
155 
100 
1900 
82 
aNo of women 
502 increased (negative selection). In figure 1 mean PRL levels were shown 
during active treatment with CV 205-502. The inset shows also the mean PRL 
curve using the last PRL measurement of each woman who stopped active 
treatment between weeks 8 and 48 or 12 and 52, respectively at each time 
point thereafter. Table 3 summarizes the (pre)treatment PRL levels in all women 
in relation to the dose of CV 205-502 that was used at the time of discontinuation 
50 
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Figure 1 Mean serum prolactin (±SEM) during active treatment with CV 205-502 (open squares) 
Inset Same data and mean serum prolactin (±SEM) if the last measured serum prolac-tin level 
in each woman who discontinued treatment before 52 weeks is taken into account at each time 
penod thereafter (closed diamonds) 
Table 3 Prolactin concentrations3 before and at discontinuation of CV 205-502 intake in relation 
to the dosage of the drug at discontinuation 
CV dosage at 
discontinuation 
of treatment 
mg 
No of 
women 
Pretreatment 
prolactin 
concentration 
mU/l 
Prolactin 
concentration at 
discontinuation 
mU/l 
Women with prolactin 
< 800 mU /I 
No Percent 
0 05 mg 
0 075 mg 
0 100 mg 
0 125 mg 
0 150 mg 
17 
8 
9 
1 
6 
2081 ±238 
3587 ± 509 
3789 ± 356 
4700 
5327 ± 947b 
256 ±41 6 
505 ± 95 4 
885 ± 140 5 
250 
1255 ±246 9 
17 
6 
6 
1 
1 
100 
75 
66 
17 
'Results are expressed as mean ± standard error of the mean 
bLess than 0 01 as compared with 0 050 mg 
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of drug intake or at 52 weeks and also indicates the number of women who 
had normalized their PRL level (< 800 mU/1) Of 41 women, 71% normalized 
their serum PRL on a CV 205-502 dose of =ξ 0 100 mg 
Menstrual Cycle 
Within 12 weeks of active treatment 19 of the 25 amenorrhoeic women had 
menstruated at least once, and at the end of treatment only 1 woman was still 
suffering from amenorrhoea Her serum PRL concentration at the end of treatment 
was 990 mU /1 In the 11 women complaining of oligomenorrhoea, the cycle 
normalized and became regular within 8 weeks in all of them Pregnancies 
occurred within the 12-month period in 4 of the 11 infertile women Mechanical 
contraception was only to be stopped when the cycle had become regular, which 
explains why the pregnancies occurred between 4 and 11 months of active 
treatment, ι e , in months 4,6, 10, and 11 Two pregnancies ended in spontaneous 
abortions, the other two produced healthy children After 52 weeks pregnancies 
occurred in 3 additional women 
Galactorrhoea 
Spontaneous milk discharge and discharge by palpation improved significantly 
or disappeared completely within 12 weeks in 13 of the 24 women with this 
complaint At the end of the treatment period at 52 weeks, only 2 women still 
reported mild galactorrhoea The last measured serum PRL levels m these two 
women were 2100 and 530 mU /L, respectively 
Tolerabdity 
During the first 4 weeks, dizziness and tiredness were reported once in both 
groups Acne was reported as a side effect once in the placebo group Only 
nausea (6 in the CV 205-502 group and 1 in the placebo group) and headache 
(7 versus 4) were reported more frequently m the CV 205-502 group at 2 weeks 
of treatment, but not any longer at 4 weeks Thus, the adverse reactions occurring 
mostly at the beginning of treatment, were mild or occasionally moderate in 
intensity and in none of the women led to study discontinuation During the 
remaining 9 months, the adverse reactions disappeared except for slight nausea 
which remained in two patients This complaint was not dose related and was 
noted especially during the night if awake 
In the 12 women treated with Parlodel® in the past whose tolerabihty was judged 
to be fair, none reported adverse reactions dunng treatment with CV 205-502 
severe enough to demand study discontinuation Also, the 9 patients with poor 
tolerance of Parlodel® in the past could continue the use of CV 205-502 with 
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considerably fewer side effects The 2 patients who did not respond at all with 
a lowering of their serum PRL level while treated with Parlodel® (maximum 
dose 40 and 15 mg, respectively) showed a significant decrease of prolactin 
while under treatment with CV 205-502 (PRL decline from 6400 and 5800 
to 990 and 2100 mU /1, respectively), on dosages of 0 150 mg 
Safety 
No clinically significant effects on blood pressure were observed at any of the 
visits nor did any of the women express complaints indicating orthostatic 
hypotension Extensive haematological and biochemical parameters in blood and 
urine, measured normal at baseline, remained so without clinically significant 
changes that could be attributed to treatment with CV 205-502 Also all physical 
examinations remained without changes throughout the study In eight women, 
five in the placebo started group, ECG changes were observed during the study 
penod These changes occurred in both directions (from normal to borderline 
and vice versa), and in no case was an alteration judged clinically significant 
Changes were seen as those that may occur when serial ECGs are recorded 
within the same population over a longer period of time No clinical symptoms 
or signs of heart problems developed 
DISCUSSION 
The objectives of this study were to ascertain the dosage at which CV 205-
502 exerts a clinically relevant PRL suppressant effect in hyperprolactinaemic 
patients and also to assess tolerability and safety of this drug The 41 patients 
who volunteered were all suffering from persistent hyperprolactinaemia with 
PRL levels > 2000 mU/L From the fact that 71% of them normalized their 
serum PRL levels with a dose of CV 205-502 of ^ 0 100 mg once daily, the 
effectiveness of this drug is clearly demonstrated 
Not all women normalized their PRL levels during this 12-month study This 
is at least in part explained by the fact that the dosage could only be increased 
to 0 150 mg/d After the 12-month period, these women have been followed 
further with a gradual increase in the dose of CV 205-502 to a maximum of 
0 500 mg once daily at time of preparing this paper Within this dose range, 
all women except two have responded with a complete PRL normalization These 
2 women have, however, shown significant decrease in their serum PRL 
concentrations from 6400 and 5800 to 990 and 2100 mU/I respectively The 
majority of the women had been treated with Parlodel® in the past, of which 
21 showed a fair or poor response to this drug It is interesting to note that 
all of them showed a significant decrease in their serum PRL levels while treated 
with CV 205-502 Even more promising is the fact that the 8 women with 
a fair response to Parlodel® in the past all normalized their serum PRL levels 
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while treated with CV 205-502, whereas the 2 Parlodel® nonresponders also 
showed significant PRL decrease while treated with CV 205-502. Therefore, 
this study strongly suggests that CV 205-502 is at least as effective in its serum 
PRL· lowering capacity as Parlodel® is. However, prospective, double-blind trials 
have to prove this hypothesis. These studies are at present ongoing. 
An important observation during this study was the fact that all women could 
continue the intake of CV 205-502 for at least 12 months and none of them 
discontinued due to intolerability. As mentioned in the introduction, CV 205-
502 has specifically been designed as a Dj receptor agonist with low binding 
to the D, receptor (4). The remarkable observation that all women tolerated 
CV 205-502 very well proves that this approach to drug design is successful. 
This is further underlined by the fact that women tolerating Parlodel® rather 
poorly all could continue treatment with CV 205-502 and also told the observers 
that, in comparison with Parlodel®, in their opinion, the tolerability of CV 205-
502 was better. As for the PRL suppressant effect of CV 205-502 the ongoing 
prospective, double-blind trials have to prove whether CV 205-502 is, indeed, 
better tolerated than Parlodel®. Although the drug is a specific D2 receptor 
agonist, a favorable effect in eliminating side effects may also be due to the 
longer pharmacological action of the drug (5). Therefore, it is sufficient to 
administer the drug once daily at bedtime, as side effects are less likely to be 
noticed during sleep. 
Several studies have shown in the past that as PRL normalizes while on dopamine 
agonist treatment, galactorrhoea improves or disappears and fertility is restored 
(9-14). Although this was not the aim of this study, the observations of pregnancies 
while on CV 205-502 and the disappearance of galactorrhoea, indeed, indicate 
that CV 205-502 in this respect is not different from other dopamine agonists. 
Until now four children have been born to women in whom conception took 
place while on CV 205-502 treatment. All children have been healthy. No special 
caution is necessary in pregnancy concerning the use of CV 205-502. Animal 
data have shown no harmful effects of the drug to offspring (15), and all clinical 
studies published so far (6-8), as well as the data from this study, indicate that 
CV 205-502 is safe. The extensive tests of urine, blood and biochemical 
parameters did not reveal any significant change from normal. Also, while on 
treatment, physical examinations, blood pressure, and pulse rate remained within 
normal range. Of special interest is the fact that no significant changes were 
observed indicating orthostatic hypotension, although we took great care to 
measure both the blood pressure and pulse rate exactly after 3 minutes' standing. 
Other dopamine agonistic drugs like Parlodel® indeed give rise to a significant 
change in blood pressure while changing posture (1). From a clinical point of 
view, all ECG recordings remained normal while on treatment, although from 
time to time some changes were seen. However, no complaints or findings 
indicated changes in cardiac function while on treatment. 
We therefore conclude that CV 205-502 shows very promising PRL lowering 
effects in hyperprolactinaemic women. It is also a well-tolerated drug, and we 
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suggest that the basic dose should be 0 075 mg once daily at bedtime instead 
of 0 050 mg 
Although >70% of all women with PRbrelated gynaecological disorders will 
normalize their serum PRL level on 0 100 mg once daily, our data also indicate 
that the higher the serum PRL level at initiation of therapy, the higher the dosage 
of CV 205-502 necessary to normalize prolactin We therefore also suggest 
that in women with very high prolactin levels, CV 205-502 should be increased 
rather rapidly stepwise from 0 075 mg a day to 0 150 mg/d, etc The drug 
appears safe, well tolerated and while PRL normalizes, galactorrhoea disappears 
and fertility restores Further prospective, randomized, and double-blind trials 
have to prove the superiority of CV 205-502 as compared with Parlodel® and 
the safety of offspring resulting from treatment 
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CHAPTER 5 
CV 205-502, A NEW DOPAMINE AGONIST, 
VERSUS BROMOCRIPTINE IN THE TREATMENT 
OF HYPERPROLACTINAEMIA 
P.FM. van der Heijden, W de Wit, J Brownell, J. Schoemaker and R. Rolland 
European Journal of Obstetrics and Gynaecology and Reproductive Biology 1991,40 111 
ABSTRACT 
Forty seven hyperprolactinaemic patients with serum prolactin (PRL) concentrations persistently 
above 1500 mU/l were treated with the new dopamine agonist CV 205 502 or bromocnptine 
in a prospective, randomued and double-blind fashion during a 24-week period Two women had 
to be excluded because of poor compliance in the first month Therefore 45 patients remained 
tor evaluation 81% of the patients in the CV 205 502 group and 70% of the patients in the 
bromocriptine group normalized their prolactin levels within the study penod with a treatment dose 
as permitted in this protocol In general serum prolactin normalized within 8 to 12 weeks of treatment 
There were no differences between the two tested drugs regarding restoration of the menstrual 
cycle or disappearance of galactorrhoea Both drugs gave rise to adverse reactions, especially during 
the initiation of therapy However, the adverse reactions reported dunng CV 205-502 treatment 
were less severe and persistent than those attributed to bromocnptine Patient acceptance of the 
new drug with regard to tolerability was judged by 90% of the women in that treatment group 
as very good or good, while 75% of those treated with bromocriptine evaluated its tolerability 
as very good or good 
We conclude that CV 205-502 is highly effective in the treatment of hyperprolactinaemia with 
concomitant restoration of gonadal function and prevention of galactorrhoea The tolerability of 
the drug seems better than of bromocnptine and therefore this drug is of value in the treatment 
of hyperprolactinaemic patients 
INTRODUCTION 
The ergot alkaloid derivative bromocriptine has become the standard dopamine 
agonist for the treatment of hyperprolactinaemia ( 1 -4). Although in general well 
tolerated, its use has been hampered in some individuals by its adverse reactions 
(5-6). This is especially so in women with mild hyperprolactinaemia. A new 
dopamine agonist with a better side effect and adverse reaction profile could 
therefore be of value. CV 205-502 (benzo[g]quinoline) is the first non-ergot 
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dopamine agonist (7). It has been specifically designed as a selective DT agonist 
with little or no D, receptor agonist activity. Its potency has been estimated 
to be about 35-times greater than that of bromocriptine (8). In healthy volunteers 
the duration of its action indicates that the drug is suitable for once daily 
administration (9). In early studies in healthy volunteers and hyperprolactinae-
mic patients, no clinically significant adverse reactions or changes in safety 
parameters were observed (10-12). The reported adverse reactions were always 
mild or moderate and none of the volunteers or hyperprolactinaemic patients 
had to terminate treatment prematurely. Several of the hyperprolactinaemic 
patients in early studies with CV 205-502 had in the past shown resistance 
or experienced severe adverse reactions during treatment with bromocriptine 
or other commercially available dopamine agonists (13-14). This strongly 
suggested a more favorable adverse reaction profile of CV 205-502 as compared 
to other dopamine agonists. It was therefore decided to explore in a prospec-
tive, double-blind and randomized fashion whether the acute and long-term 
tolerability and safety of CV 205-502 would show a significant difference from 
that of bromocriptine. 
MATFRIALS AND METHODS 
Forty-seven women with longstanding hyperprolactinaemia with or without a 
microprolactinoma were included in the study. Pretreatment serum prolactin 
levels were persistently >1500 mU/1 (upper normal range is ^800 mU/1, 36 
mU/1 = 1 ng/ml). They were otherwise healthy women between 18 and 47 
years of age and all agreed to participate for a 24-weeks period, unless side 
effects or adverse reactions required premature discontinuation of treatment. 
The study protocol had been approved by the ethical committees of the 
participating hospitals and all women gave their written consent prior to entrance 
into the study after both oral and written information. The study was conducted 
according to the Tokyo amendment of the Declaration of Helsinki. 
Thirteen women suffered from secondary amenorrhoea, 10 from oligomenorrhoea 
and 1 woman had a regular cycle despite hyperprolactinaemia. The remaining 
23 patients discontinued their dopamine agonist therapy at least 1 month preceding 
the study and repeated prolactin measurements thereafter showed serum prolactin 
to be persistently above 1500 mU/1. Thirteen patients wanted to achieve 
pregnancy during the study. In all of them, three consecutive ovulatory cycles 
were monitored before mechanical contraception was stopped and conception 
was pursued. Table 1 shows pretreatment findings in the two study groups. It 
can be concluded that the randomization was successful. 
All women received capsules of identical appearance in two packets, one for 
the morning and one for the evening intake, containing either CV 205-502, 
bromocriptine or a placebo. They all took two capsules a day, during breakfast 
and with a snack at bedtime. The starting dose for bromocriptine was 1.25 
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Table 1 Anamnestic and descriptive dala of patients, randomized into the CV 205-502 group (CV) 
or Bromocriptine (BR) group 
Item 
No of women 
Age (years, mean ± SEM) 
Height (cm, mean ± SEM) 
Weight (kg, mean ± SEM) 
Infertilily·1 
Galactorrhoea 
Amenorrhoeah 
Oligomenorrhoeac 
Previous bromocriptine med 
Microadenoma 
CV 
23 
3 1 8 ± 1 36 
167 1 + 125 
65 1 ± 2 36 
7 
10 
7 
4 
15 
9 
BR 
24 
342 ± 137 
164 8 ± 136 
62 4 ± 2 54 
6 
5 
6 
6 
19 
8 
•"more than 1 year 
bmore than 6 months 
between 6 weeks and 6 months 
mg at bedtime with a placebo morning capsule during the first 3 days, followed 
by 1.25 mg at breakfast and at night for the next 3 days (days 4-6). Thereafter 
bromocriptine 2.5 mg was taken twice daily. The starting dose of CV 205-
502 was 0.025 mg at bedtime with a placebo capsule during the morning for 
the first 3 days, followed by 0.05 mg for the next 3 days (days 4-6) with thereafter 
0.075 mg at bedtime. CV 205-502 treated women always took a placebo capsule 
during the morning. After 8 and 16 weeks the dose of bromocriptine or CV 
205-502 could be adjusted according to the measured prolactin suppressant effect. 
CV 205-502 could be increased to 0.10 or 0.15 mg at bedtime; bromocriptine 
could be increased in a similar way to 7.5 mg by changing the evening capsule 
to one containing 5 mg bromocriptine or 10 mg changing both the morning 
and evening capsules to 5 mg. All medication packets were numbered and each 
patient received a number in correspondence with the number on the medication 
packages she could use. To guarantee the double-blindness of the study a change 
in dosage meant a change of both the packets containing morning and evening 
capsules. 
Physical examinations, extensive blood and urine analysis and ECG evaluations 
were performed at baseline and repeated throughout the study at 4-week intervals. 
Serum prolactin, body weight, blood pressure and pulse rate (supine and standing) 
were also measured at 4-week intervals. Each individual patient was seen 
throughout the investigation period by the same investigator. At each visit the 
women were examined for the presence of galactorrhoea and questioned regarding 
the regularity of the cycle and the occurrence of adverse reactions by way of 
a questionnaire. 
Serum prolactin was measured by use of commercially available radioimmunoas-
says (Farmos Diagnostica, Turku, Finland; Medgenix Diagnostics, Brussels 
Belgium). The upper limit of normal in menstruating women is 800 mU /1. All 
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other laboratory measurements (blood chemistry, haematology, urine analysis) 
were performed applying specific and sensitive standard laboratory procedures. 
All results are expressed as geometric mean values ± standard error of the 
mean (SEM), and the Wilcoxon signed-rank test was used for calculations of 
differences between the two groups. 
RESULTS 
Patient population 
Two women were excluded from the study within 2 weeks from beginning of 
drug intake due to poor compliance, 1 in each group. Their data are completely 
excluded from evaluation. An additional woman in the CV 205-502 group had 
to be excluded due to violation of the protocol at 8 weeks. Up to week 8 of 
the trial her data are included in the analysis. An additional 5 women, 1 in 
the CV 205-502 group and 4 in the bromocriptine group, withdrew after week 
4 and 4, 4, 4, 8 respectively, due to adverse reactions. Until withdrawal, their 
data are included in the analysis. Therefore, 21 patients in the CV 205-502 
group and 20 in the bromocriptine group were available for evaluation throug-
hout the first 8 weeks, 20 and 19, respectively, thereafter. 
Serum prolactin concentrations 
The mean serum prolactin profiles in the 2 treatment groups, calculated after 
the code was broken at 24 weeks, are shown in figure 1. In both groups a 
highly significant decrease in serum prolactin concentrations occurred within 
the first few weeks (P < 0.001) with mean prolactin levels well below the upper 
limit of normal thereafter in both groups. There was no significant difference 
in prolactin levels between the groups. After 8 weeks of treatment 17 (81%) 
of the 21 évaluable patients in the CV 205-502 group had normalized their 
serum prolactin levels. Serum prolactin levels of the 1 woman who withdrew 
from the study at 8 weeks because of adverse reactions were 130 mU/1 at 
discontinuation. None of the remaining 4 women with elevated prolactin levels 
at 8 weeks normalized during the next 4 weeks despite a dose increase of CV 
205-502. At 24 weeks, 2 of the remaining 4 women had normal serum prolactin 
levels with daily CV 205-502 doses of 0.150 mg. The remaining 2 women 
had persistently elevated concentrations of 1900 and 1700 mU/1, respectively, 
despite daily CV 205-502 doses of 0.150 mg, the highest dose allowed within 
the protocol. 
In the bromocriptine treated group 14 (70%) of the 20 évaluable women at 
week 8 had serum prolactin levels within the normal range. Three women 
withdrew from the study at 4 weeks and 1 at 8 weeks due to side effects. The 
remaining 6 women had their bromocriptine dose increased to 7.5 mg. One 
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Figure 1. Serum prolactin levels (mean ± SEM) in CV 205-502 (closed diamonds) and bromocripti­
ne (open squares) treated women. 
reached normal serum prolactin concentrations at week 12, an additional 2 
normalized between 12 and 24 weeks and 3 still had hyperprolactinaemia at 
24 weeks, with values of 2900, 2200 and 1200 mU/1, respectively, despite a 
daily bromocriptine dose of 10 mg, the highest allowed within the protocol. 
Menstrual cycle 
Table 2 summarizes cycle characteristics previous to and during treatment. Thirty-
two of the évaluable patients had dopamine agonist treatment until 1 month 
prior to this study, 21 of them were menstruating regularly. They continued 
to have regular menses throughout the study. Eight women had oligomenorrhoea. 
At 8 weeks only 4 patients had still oligomenorrhoea, and at 24 weeks all women 
still in the study, reported regular menstrual cycles. The remaining 3 women 
had amenorrhoea and developed a regular menstrual pattern at the end of therapy. 
The randomization in groups is listed in table 2. 
Amenorrhoea. Seven women in the CV 205-502 group and 6 in the bromocripti-
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Table 2 Cycle characteristics of the CV 205-502 and bromocnptme-treated groups at initiation 
of therapy and at 8, 12 and 24 weeks of treatment 
CV 205-502 
Week 0 8 12 24 
No of patients 23 
excluded 1 1 1 -
evaluable 22 21 20 20 
Amenorrhoea 
with" 1 1 1 -
without" 6 3 1 -
Oligomcnorrhoea 
with2 3 2 - 2 
withoul" 1 1 - -
Regular 
with3 10 13 17 15 
without" 1 1 1 1 
Pregnancy 2 
Bromocnpline 
0 8 12 24 
24 
1 3 1 -
23 20 19 19 
г - - -
4 2 2 2 
5 1 - 1 
1 - - -
11 16 16 14 
1 1 1 
1 
••with dopamine agonist treatment 
"without dopamine agonist treatment 
ne group were amenorrhoeic at initiation of therapy. In the CV 205-502 group 
3 reported regular menstruations at 8 weeks and the remaining 4 were still 
amenorrhoeic. At 24 weeks all had menstruated, although 2 had oligomenorrhoea. 
Of the 6 amenorrhoeic women in the bromocriptine group, 2 responded with 
normalization and regular menstruation at 8 weeks. At 24 weeks only 2 women 
in this group remained still amenorrhoeic. 
Oligomenorrhoea. At initiation of therapy 10 women were oligomenorrhoeic. 
The CV 205-502 group contained 4 of these patients. One was excluded after 
4 weeks of treatment due to adverse reactions and an additional one after 8 
weeks due to violation of the protocol. Both had still oligomenorrhoea. The 
remaining 2 women were still oligomenorrhoeic at 8 weeks, but developed regular 
cycles thereafter. In the bromocriptine group were 6 oligomenorrhoeic patients. 
One woman was also excluded due to adverse reactions after 4 weeks of treatment. 
Four women menstruated regularly at 8 weeks and the last one developed regular 
cycles shortly thereafter. 
Regular menstrual cycles. One patient (C V 205-502 group) menstruated regularly 
at initiation of therapy and continued to do so while in the study. One woman 
in the bromocriptine group menstruating regularly developed oligomenorrhoea 
at the end of therapy despite normal serum concentrations of prolactin. Of the 
women still in the study at 24 weeks, therefore, 80% in the CV 205-502 group 
and 79% in the bromocriptine group were menstruating regularly. 
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Pregnancies 
Thirteen patients (7 in the CV 205-502 group and 6 in the bromocriptine group) 
wanted to conceive, of whom 10 had regular ovulatory cycles within 2 months 
of treatment. After 3 ovulatory cycles had been recorded, 11 of them stopped 
mechanical contraception. Two patients conceived during treatment weeks 20 
and 24, respectively. They both belonged to the CV 205-502 group and their 
prolactin concentration at conception had normalized, being 540 and 150 mU/1 
at dosages of 0.1 and 0.15 mg CV 205-502, respectively. A third patient conceived 
during treatment week 18 and belonged to the bromocriptine group. Her prolactin 
level was 100 mU/1 and her dose 7.5 mg bromocriptine. During a 6-month 
open label follow-up period when all women received CV 205-502, an additional 
4 women conceived, 3 who had started with CV 205-502 and 1 who had started 
with bromocriptine. 
Gahctorrhoea 
At initiation of therapy, 15 women had signs of galactorrhoea; 10 (55%) in 
the CV 205-502 group and 5 (32%) in the bromocriptine group. In 13 of them 
galactorrhoea disappeared rapidly during treatment, and at 8 weeks only one 
patient in each group still had this complaint. At 24 weeks of treatment 
galactorrhoea had disappeared in all patients. 
Tolerability 
Five women discontinued treatment due to poor tolerability within the first 8 
weeks, 4 in the bromocriptine group and one in the CV 205-502 group. Patients 
in the former group reported dizziness (2x), headache (lx) and nausea (2x) as 
reasons for withdrawal, whereas the patient in the latter withdrew from treatment 
due to nausea and headache. As mentioned earlier there were three additional 
dropouts, all beyond 8 weeks of treatment, due to poor compliance in two instances 
(one in each group) and one due to violation of the protocol (CV 205-502 
group). Therefore 21 patients in the CV 205-502 group and 20 in the bro-
mocriptine group were available for further evaluation concerning tolerability 
after 4 weeks. Table 3 summarizes the adverse reactions in the two groups. 
In general, the recorded adverse reactions were mild and often transient, especially 
in the CV 205-502 group. Most frequent adverse reactions in the CV 205-
502 group were nausea and headache, whereas in the bromocriptine group besides 
these complaints, dizziness and obstipation were also recorded rather frequently. 
From week 8 onwards the dose could be increased, and this may have influenced 
the frequency of reported adverse reactions thereafter. 
At 24 weeks of treatment.just before breaking the randomization code, all women 
still in the study, including the drop-outs, were asked to judge the overall 
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Table 3 Adverse reactions in CV 205-502 and bromocriptine treated women throughout the study 
period (one patient may have reported more than one complaint) 
Group 
Week 
Complaint 
Nausea 
Headache 
Dizziness 
Obstipation 
Anorexia 
Tiredness 
Stuffy nose 
Stomach pain 
Total No of 
registered complaints 
No of patients 
with complaints 
4 
12 
6 
3 
1 
1 
-
-
4 
27 
18 
CV 205-502 
8 
4 
2 
2 
1 
1 
-
-
3 
13 
10 
12 
2 
-
1 
-
-
-
-
1 
4 
3 
24 
-
1 
3 
-
-
1 
-
-
5 
5 
Bromocriptine 
4 
7 
3 
4 
5 
2 
2 
2 
3 
28 
16 
8 
4 
2 
4 
2 
I 
4 
-
1 
18 
9 
12 
3 
2 
2 
1 
-
-
-
-
8 
6 
24 
1 
3 
1 
1 
-
-
-
-
6 
5 
tolerability of the treatment as very good, good, moderate or poor. In the CV 
205-502 group 59% of the patients reported the tolerability to be very good, 
32% to be good whereas one patient (5%) judged the tolerability as moderate 
and the last patient (5%) as bad. In the bromocriptine treated group these figures 
were, respectively, 46, 29, 8 and 17%. 
Safety 
At entry into the study all safety parameters were within normal limits in all 
of the patients. During the entire treatment period no clinically significant changes 
occurred in routine physical examinations, blood chemistry, haematology or urine 
analysis except for one woman in the bromocriptine group who had a significant 
increase in her CPK at 12 weeks of treatment due to an accident with muscle 
damage. The CPK value normalized rapidly thereafter. Neither could any 
significant effect on blood pressure be demonstrated in both groups nor were 
complaints indicating (orthostatic) hypotension mentioned. The ECG recordings 
did not change throughout the observation period except in two instances, one 
in each group, where clinically non-significant transient signs of atrioventricular 
blocks were seen. Both women had shown ECG recordings in the past with 
the same transient changes. Such findings are likely to be seen within any randomly 
controlled group when serial ECGs are recorded. 
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DISCUSSION 
This study shows that CV 205-502 is at least as effective as bromocriptine 
in the normalization of serum prolactin in hyperprolactinaemic women Within 
the doses used, 81% of the patients in the CV 205-502 group had normalized 
their serum prolactin compared to 70% in the bromocriptine group This strong 
prolactin suppressant effect of 0 075 mg CV 205-502 administered once daily 
has also been shown in several open studies in hyperprolactinaemic women (9-
14) The pharmacological action of this new compound is significantly longer 
than that of bromocriptine (11), allowing once daily administration This 
advantage increases the compliance with CV 205-502 From this study and 
from other dose finding studies (7,10,11) we therefore can conclude that once 
daily administration of CV 205-502 of 0 075 mg is at least as effective as 
2 5 mg bromocriptine bid Although in this double blind study, the CV 205-
502 dose of 0 075 mg was reached via stepwise titration similar to that generally 
used at the start of bromocriptine therapy, previous studies had documented 
that a starting dose around this level is well tolerated (10,13,14) 
As expected, this study also convincingly demonstrates that once prolactin reaches 
normal values, gonadal function restores At the end of treatment all normoprol-
actmaemic women had regular menstrual cycles except for 1 woman in the 
CV 205-502 group who had ohgomenorrhoea (despite normal prolactin levels) 
If restoration of gonadal function is the aim of treatment in hyperprolactinaemic 
women as it is in case of infertility, it can be postulated with great certainty 
that normal menstrual function will re-occur once normoprolactinaemia is reached 
(2,3,15) There was no difference between the two tested drugs in this regard 
Also, galactorrhoea often disappears rapidly while under treatment and, like 
the restoration of normal gonadal function, this is most likely linked to the 
control of the elevated prolactin rather than to the type of dopamine agonist 
used 
The tolerability profile of CV 205-502 seems better than that of bromocriptine, 
which can be concluded from the following observations. 
In the bromocriptine group 4 dropouts were recorded due to adverse reactions 
against only 1 in the CV 205-502 group When further analyzing the data, 
it appeared that 10 of the patients in the CV 205-502 group had shown intolerance 
to bromocriptine in the past Nine of these women tolerated CV 205-502 well, 
while the remaining one dropped out due to adverse reactions Four of these 
women had in the past shown resistance to bromocriptine up to the doses used 
in this study without normalization of prolactin During this study, 3 of them 
normalized while under CV 205-502 treatment whereas the fourth patient was 
the dropout with adverse reactions Similar observations have been made by 
others ( 16) 
The adverse reactions mostly recorded in the CV 205-502 group were nausea, 
stomach pain, headache and dizziness Only in one instance these adverse reactions 
became so severe that drug intake had to be stopped Similar adverse reactions 
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also occur in bromocriptine-treated women but, in addition, a wider scale of 
side effects can be seen, like tiredness, obstipation, anorexia and stuffy nose. 
Finally, when the participating women were asked at the end of the study previous 
to breaking the code, how they had accepted the drug therapy, 90% of the 
CV 205-502-treated women judged the acceptability as good or very good versus 
75% in the bromocriptine group. In our opinion this, indeed, indicates that the 
new drug has a better tolerability profile than bromocriptine and therefore widens 
the dose range in which it can be prescribed. Case reports have been published 
in which women intolerant or resistant to bromocriptine did respond to high 
doses of CV 205-502 with normalization of their serum prolactin levels (16). 
In this short term study period of 6 months, none of the drugs gave rise to 
significant changes in the evaluated safety parameters. For bromocriptine this 
was as expected, since the drug has been widely used and has been rccogni/ed 
as very safe. Studies with CV 205-502 so far have also failed to demonstrate 
any hazard of this drug (12-14). There are, however, rather limited data on 
the safety of the drug during early pregnancy in humans although at present 
some 30 children have been born after exposure to CV 205-502. In animal 
experiments no toxic or teratogenic effects have been shown in the offspring 
(Personal communication Sandoz Ltd, Basle, Switzerland). This point has to 
be investigated very carefully during further studies with CV 205-502 and in 
infertile women it is recommended that drug intake should stop as soon as the 
menstrual period has been missed by more than 3 days. 
In conclusion, the results from this double-blind study clearly show that CV 
205-502 is highly effective in the treatment of hyperprolactinaemia, the adverse 
reaction profile is tolerable, with 90% of patients assessing tolerability as good 
or very good at the end of treatment. The once daily dose schedule is convenient 
and allows little or no interference of possible side effects with daily activities. 
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CHAPTER 6 
LACTATION INHIBITION BY THE NEW DOPAMINE 
AGONIST CV 205-502 
P.F.M. van der Heijden, J.A.M. Kremer, J. Brownell, R. Rolland 
British Journal of Obstetrics and Gynaecology 1991,98 270 
ABSTRACT 
In an open pilot study with a parallel group design, 30 bottlefeeding women were randomly assigned 
in a two to one ratio to receive either the new dopamine agonist CV 205-502 or bromocnptine 
for lactation inhibition Ten women who intended to breastfeed served as normal controls 
All treated women reached prepregnant prolactin levels within 72 h with once-daily 0 075 mg 
of CV 205-502 or twice-daily 2 5 mg of bromocriptine, at starting doses of 0 05 mg and 2 5 
mg respectively Fifteen of the 20 women treated with CV 205-502 reported breast symptoms, 
50% occurring on days 3 and 4 of treatment Three of the 10 women treated with bromocnptine 
had breast symptoms between days 2 and 28 
Overall efficacy and tolerance in the two groups was very good Side effects did not differ between 
the groups, with the exception of pulse rate in the standing position, which was significantly higher 
in the bromocriptine treated group than in either the CV 205-502 group (P=0 02) or the breastfeeding 
group (P<0 01) The coagulation tests (fibrinogen, AT III, PTT and APTT) showed no significant 
differences between the three groups 
INTRODUCTION 
There are many reasons why puerperal lactation may need to be inhibited, social 
reasons being the most common (1-2). Effective suppression of puerperal lactation 
had long been a problem until the introduction of the dopamine agonist 
bromocriptine in the IQTO's (3-6), but several recent reports have implicated 
bromocriptine in various side effects in the puerpenum (7-10). 
The non-ergot dopamine agonist CV 205-502 is an octahydrobenzo[g]quinoline 
(11) which has demonstrated strong prolactin lowering effects in various animals, 
in healthy volunteers and in hyperprolactinaemic patients (12-15). Approximately 
80% of the hyperprolactinaemic patients treated during a dose-titration study, 
achieved normal prolactin levels with once daily doses of CV 205-502 between 
0.05 and 0.10 mg (16). The drug has been generally well tolerated, and reported 
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adverse effects were transient nausea, sleepiness and headache during the initiation 
of therapy ( 14). Since studies so far indicate that the drug is safe (ECG recordings, 
physical and laboratory blood and urine tests) it was expected that the strong 
24 h prolactin suppressant properties of CV 205-502 should offer an effective 
and well accepted alternative for use in inhibition of puerperal lactation. 
Therefore it was decided to study prospectively the clinical and prolactin 
suppressant effects of a once-daily dose of CV 205-502 in the prevention of 
postpartum lactation. A parallel group received a twice-daily dose of bromo-
criptine (Parlodel®, Sandoz Ltd, Basle). The safety of CV 205-502 was assessed 
by way of standard laboratory blood tests, selected measures of coagulation 
and fibrinolysis and physical and ECG examinations. The assessment of vital 
signs, coagulation and fibrinolysis was also performed in the bromocriptine treated 
patients and in a control group of 10 normal women who intended to breastfeed. 
MATERIALS AND METHODS 
Study design 
In this first study to test CV 205-502 in the suppression of postpartum lactation, 
an open model was chosen to examine two aspects of the suppression of 
postpartum lactation: (i) to find the optimal dose of CV 205-502 and to compare 
its effect with that of bromocriptine both clinically and on plasma prolactin 
levels; (ii) to assess the safety of CV 205-502 by means of ECG and complete 
laboratory urine and blood tests, including tests of coagulation and fibrinolysis. 
A two to one ratio was chosen to receive either CV 205-502 (20 women) or 
bromocriptine (10 women). The patients and investigative staff were aware of 
the treatment of each patient. Ten women who intended to breastfeed were 
selected to serve as normal controls for vital signs and tests of coagulation and 
fibrinolysis. The study had been approved by the ethical committee of the hospital 
and all women gave their written informed consent to participate. 
All women had regular menstrual cycles previous to their pregnancies and had 
conceived spontaneously. They had no problems during the pregnancy and were 
delivered between 37 and 43 weeks gestation. None of the women used medication 
which could interfere with the administered dopamine agonists, and intake of 
oral contraceptives was to be delayed until day 42 postpartum. 
The treatment was started within 24 h after delivery. In the CV-group, CV 
205-502 was given as a daily oral dose at bedtime of 0.05 mg (day 1), 0.075 
mg (days 2-14) and 0.05 mg (days 15-21). In the bromocriptine-group, bro-
mocriptine was given twice daily 2.5 mg (days 1-14), followed by once daily 
2.5 mg (days 15-21) to prevent rebound lactation (6). If breast tenderness or 
milk production was recorded at any time after day 4, the bedtime dose of 
CV 205-502 could be increased to 0.125 mg up to day 14 and a further dose 
increase of 0.05 mg daily could be given if necessary. 
69 
Assessment 
The patients were visited for assessment on days 0 (day of delivery), 1, 2, 3, 
4, 6, 9, !2, 15, 18, 22, 24, 28, 35 and 42 On these days blood samples were 
obtained to estimate prolactin (PRL) levels The women were questioned about 
breast symptoms (milk production, congestion and pain) and side effects The 
following rating scale was used none, mild, moderate (no treatment required) 
and severe (treatment required) The amount of milk secretion was classified 
as follows none, mild (few drops), moderate (spontaneous secretion) and severe 
(stream of milk) These daily observations were graded according to the seventy 
and duration of the symptoms as follows very good, no symptoms or mild short-
lasting symptoms « 2 4 h ) , good, mild long-lasting symptoms (>24h) and/or 
moderate short-lasting symptoms « 2 4 h ) , moderate, moderate long-lasting symp­
toms (>24h) and /or severe short-lasting symptoms « 2 4 h ) , poor, severe long-
lasting symptoms (>24h) The safety of CV 205-502 was tested by routine 
physical examination, ECG and laboratory tests (haemoglobin, platelets, leuc­
ocytes and differential count, urea, creatinine and liver enzymes) on days 0 and 
42 Coagulation tests (fibrinogen, activated partial thromboplastine time (APTT), 
prothrombine time (PTT) and antithrombme III were performed on days 0, 1, 
12 and 42 Pulse rate and blood pressure were recorded at each visit in the 
supine position and after 3 minutes' standing to examine the possible presence 
of orthostatic hypotension The Spectna competitive solid-phase RIA from Farmos 
Diagnostica (Turku, Finland) was used for measuring PRL (sensitivity 30 mlU /1 
and inter-assay variation 9%) 
Statistics 
The Wilcoxon rank sum test was used to analyse the PRL results and other 
laboratory findings Fisher's exact test was used to compare the clinical results. 
Differences with Ρ < 0 05 were considered significant 
RESULTS 
Four women started to take oral contraceptives before day 42 post partum, 
two in the CV 205-502 group (days 15 and 26) and two in the bromocriptine 
group (days 22 and 30) When all data were examined including or excluding 
the findings or measurements in these four women, the results remained the 
same, so data from these women are included 
The characteristics of the women in the three study groups are given in table 1, 
there were no significant differences between the groups. 
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Table 1 Descriptive data of each study group 
Variable 
Age (years) mean (SEM) 
Parity 
Primiparae 
multiparae 
Mode of delivery 
vaginal 
cesarean 
Gestational age at delivery (weeks) 
37 
38 
39 
40 
41 
42 
43 
CV 205-502 
(n = :20) 
28 3(0 8) 
8 
12 
18 
2 
2 
3 
2 
6 
6 
1 
-
Bromocriptine 
(n = 10) 
27 3(0 9) 
5 
5 
8 
2 
1 
1 
-
5 
3 
-
-
Breastfeeding 
(n= 10) 
304(1 1) 
8 
2 
8 
2 
1 
-
3 
5 
-
_ 
1 
Prolactin 
Figure 1 summarizes mean prolactin concentrations in the three groups: both 
CV 205-502 and bromocriptine suppressed prolactin to the normal prepregnant 
range « 750 mU /L) within 72 h. Bromocriptine-treated women tended to 
normalize more rapidly. The calculated mean half life for prolactin suppression 
in the bromocriptine group was 0.59 (SD 0.43) and 0.87 (SD 0.33) in the CV-
group (P^O.09). In both groups a rebound phenomenon occurred after withdrawal 
of the drugs on day 21. In the bromocriptine group also an increase of prolactin 
from day 14 onwards was obvious after dose reduction. From day 35, all prolactin 
measurements were within the normal range. The prolactin profile in breastfeeding 
women was quite different with a gradual decline until day 28, with clearly 
elevated levels thereafter. The initial period was characterized by fluctuating 
levels in each woman. Blood sampling for prolactin measurement was not related 
to time of breastfeeding. 
Efficacy 
Three of the 10 women in the bromocriptine group and 15 of the 20 women 
in the CV-group reported breast symptoms. In the bromocriptine group symptoms 
were recorded for 1 to 3 days. In the CV-group, six women had symptoms 
for 1 day, six had symptoms for 2 days, two had symptoms for 3 days and 
one had symptoms for 4 days. Although the women had moderate symptoms 
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Figure 1 Mean serum prolactin (mlU /I +SEM) values during CV 205-502 (-·-) and bromocriptine 
(-о-) ireatmenl Inset mean serum prolactin (mlU /1 ±SEM) values in the breastfeeding group 
the dose was increased and the complaints disappeared. In one other woman 
the dose was increased after 3 days of increasing complaints. In the CV-group 
more than 50% of the complaints occurred during days 3 and 4 whereas in 
the bromocriptine group the complaints were much more spread out between 
days 2 and 28 No rebound lactation took place after cessation of medication. 
The final assessment of overall efficacy for the 20 women in the CV 205-502 
group was very good in 12, good in 6 women, moderate in 1 and poor in one 
(figure 2). In the bromocriptine group 8 women graded there symptoms as very 
good and the other two as moderate. The difference between the groups was 
not significant (P=0.54). 
Side effects 
In both groups side effects were reported, mostly of mild intensity and none 
72 
of the participants withdrew from the study because of side effects. Figure 2 
summarizes the overall tolerance and there was no significant difference between 
the two groups (P = 0.54). In the CV-group 10 of 20 women reported side 
effects: headache (4), dizziness (3), nausea (4), vomiting (1) and insomnia (1). 
One of these 10 women complained of nausea and vomiting on days 3 and 
4, which resulted in interruption of treatment for one day (day 4). She was 
delivered by caesarean section and the complaints were attributed to the presence 
of bowel distension. Dizziness and nausea were reported at initiation of therapy 
whereas headache was reported even after cessation of medication by two women. 
Three of 10 women in the bromocriptine group reported side effects: headache 
(2), dizziness (2) and nausea (1). In this group also dizziness and nausea occurred 
at initiation of therapy. 
overall tolerability 
CV 205-502 bromocriptine CV 205-502 bromocriptine 
very good Ш ^ good I I moderate I I poor 
Figure 2. Overall efficacy and overall tolerance as judged by the investigator in the CV 205-502 
and bromocriptine treated groups. 
Safety 
In the supine position blood pressure (systolic and diastolic) and pulse rate did 
not show significant differences between the three groups. After 3 min of standing 
blood pressure remained unchanged in all groups whereas pulse rate increased. 
There was no significant difference in the pulse rate on standing between the 
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breastfeeding control group and the CV-group (P=0 24), but the women in the 
bromocnptine-group had a significantly higher pulse rate (P<0.01) than the 
CV-group (P=0 02) 
Table 2 summarizes the changes in coagulation and fibrinolysis variables. The 
values obtained on days 0 (before drug intake) and 42 are compared; the values 
on days 1 and 12 did not differ significantly from those on day 0 (all P-values 
>0 2) and they are not shown There was no significant difference between 
Table 2 Comparison of coagulation and fibrinolysis tests on day 42 versus day 0 Number of 
measurements (n), mean difference (x) and standard error of the mean of the difference (SFM) 
are shown 
Fibrinogen (g /1) 
AT III (%) 
PPT (sec) 
APTT (sec) 
η 
18 
18 
18 
18 
CV 205-502 
χ 
-106 
8 7 
0 2 
4 8 
SEM 
0 16 
19 
0 4 
14 
η 
7 
8 
8 
8 
Bromocriptine 
χ 
-137 
5 0 
-0 4 
2 3 
SEM 
0 2 
15 
0 4 
18 
η 
10 
10 
10 
9 
Breastfeeding 
χ SEM 
-128 033 
105 3 3 
0 0 0 4 
3 9 17 
the three groups on day 0 and day 42 The post partum period was characteri/.ed 
in all women by a decrease in fibrinogen (P<0 02) and an increase in anti-
thrombine III (P<0 04), APTT tended to increase but this change was significant 
only in breastfeeding women (P=0.03). PTT remained constant. 
The results obtained from routine haematology and blood chemistry in the CV-
group did not show significant differences between days 0 and 42. The most 
persistent finding was a highly significant decrease of creatinine Phosphokinase 
(CPK) in all women (day 0: mean 210 (SD 130) units, day 42: mean 70 (SD 
80), P<0 01). 
In the CV-group ECG recordings on day 0 were normal in 18 women and 
one woman had slight tachycardia with flattened Τ waves, on day 42 all women 
had normal ECG recordings. A full general examination on days 0 and 42 did 
not show any changes which could be attributed to the use of CV 205-502. 
DISCUSSION 
Previous studies have shown dopamine agonists like bromocriptine to be effective 
in the inhibition or suppression of lactation ( 17). In the present study bromocriptine 
showed the well known profile of rapid suppression of prolactin concomitant 
with nearly complete inhibition of mammary activity. 
The new dopamine agonist CV 205-502 was very similar in its profile: rapid 
prolactin suppression and inhibition of mammary activity. The difference between 
these two drugs, which was not statistically significant, was the more rapid 
normalization of prolactin levels in bromocriptine treated women. This may 
explain why the women in the CV-group, who reported signs of mammary activity 
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tended to do so on days 3 and 4. This suggests that the initial dose of 0.050 
mg of CV 205-502 was slightly too low and should be increased to 0.075 mg. 
Indeed 0.075 mg has been recommended as a starting dose in gynaecological 
patients suffering from symptomatic hyperprolactinaemia (16). After withdrawal 
of the drugs on day 21 a significant prolactin rebound release was obvious in 
both groups. In the bromocriptine group this rebound release already began 
on day 14 when the drug dose was decreased. The difference in the patterns 
of the two curves (figure 1): a sharper rise in the CV-group and a more flattened 
curve in the bromocriptine group, indicates that after acute inhibition of pituitary 
prolactin release, an easily releasable prolactin pool remains in the lactotrophs 
for at least three weeks (18-19). Despite this rebound release, however, no signs 
of rebound mammary activity were seen. Shorter suppression of prolactin has 
been reported to result in rebound lactation in a substantial percentage of women 
(6). The mammary gland after 3 weeks of prolactin suppression is less responsive 
to prolactin. An explanation for this may be the fact that around day 21 in 
dopamine agonist treated women, ovarian activity is restored, with many women 
actually experiencing their first ovulations during this period (20). High levels 
of circulating 17/3-oestradiol, possibly in combination with progesterone, protects 
the mammary epithelium from the stimulating effect of prolactin (21). 
In this study only mild side effects of headache, nausea, dizziness and insomnia 
were reported in some women in both groups except for one patient who suffered 
of bowel distension on days 3 and 4 after an abdominal delivery. These findings 
are in agreement with previous reports that postpartum women tolerate dopamine 
agonists very well (22). 
Of great interest is the statistically significant increase in pulse rate seen in 
bromocriptine treated women compared with the CV-group and breastfeeding 
women although there were no significant changes in blood pressure. This may 
indicate that bromocriptine exerts a haemodynamic effect, which was absent 
following CV 205-502 treatment and in the breastfeeding women. This finding 
may be seen as a tendency to orthostatic hypotension in bromocriptine treated 
women which was counteracted by the increase in pulse rate. CV 205-502 treated 
women behave in this respect like breastfeeding women indicating that this drug 
has little or no influence on the cardiovascular system. This is in agreement 
with findings in volunteers and in hyperprolactinaemic patients in whom no 
influence on blood pressure and pulse rate was found (12-16). 
There were no significant differences in changes in the clotting factors between 
the treated and control group. Few data have been published on changes in 
the coagulation and fibrinolysis systems post partum. The observed changes, 
similar in all three groups, with a decrease in fibrinogen and an increase in 
antithrombin III indicates that the hypercoagulability present during pregnancy 
(23), gradually disappears. Although it has been suggested that dopamine agonists 
could influence these indices unfavorably, this study clearly demonstrates that 
neither CV 205-502 nor bromocriptine influence coagulation and fibrinolysis. 
Also in the CV 205-502 treated women, no significant changes were observed 
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in routine haematology and blood chemistry aside from the highly significant 
decrease of CPK from day 0 to day 42 This is explained by the uterine muscle 
strain during delivery and by the involution of the uterus thereafter General 
physical examinations and ECG recordings in CV 205-502 treated women 
measured previous to and after treatment did not reveal any changes, also 
indicating the safety of CV 205-502 in postpartum patients 
It can be concluded that CV 205-502 is as effective as bromocriptine in the 
prevention of puerperal lactation The drug has the advantage over bromocriptine 
that once daily administration is sufficient to produce normoprolactinaemia 
Although the number of patients in our study is small, the findings are in agreement 
with other reports suggesting that CV 205-502 is a safe drug The reported 
side effects were differed little, but in our opinion the observed difference in 
haemodynamic changes between bromocnptine and CV 205-502 treated women 
and lactating women, would favour the use of CV 205-502 Our data indicate 
that further studies are necessary to identify the optimal starting dose, 0 05 mg 
seems to be too low Therefore no definite conclusions on starting dose and 
safety of CV 205-502 in the indication of inhibition of lactation can be drawn 
with certainty from this study Further prospective tnals are needed to answer 
these questions 
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CHAPTER 7 
GENERAL DISCUSSION AND CONSIDERATIONS 
It was only during the late sixties and early seventies that the existence of human 
prolactin as a single and separate hormone next to human placental lactogen 
and human growth hormone was proven (Pasteéis 1972, Friesen and Hwang 
1973). Thereafter an explosion of publications has dealt with physiology and 
pathophysiology of prolactin in man (Nicoli 1974). Notwithstanding, the complete 
role of prolactin in many processes is still unsolved. 
A very remarkable development was the fact that during the sixties ergot alkaloids 
like bromocriptine were shown to have prolactin lowering properties in several 
animal species (Berde and Schild 1978). It was postulated that this was also 
the case in man which indeed proved to be correct. The fact that bromocriptine 
or at that time known as CB 154 (Corrodi et al. 1973) was ready for clinical 
testing at the very moment that the first radio-immuno assays for prolactin 
determination became available, has certainly accelerated our knowledge re-
garding prolactin (patho)physiology. Although originally it was suggested that 
all patients suffering from hyperprolactinaemia could be treated efficiently with 
bromocriptine, we were to discover that this was not the case: a minority of 
patients will not respond with adequate prolactin suppression (Pellegrini et al. 
1989). Furthermore, minor to severe adverse effects have been registered, nearly 
all specific to ergot derivatives. Basic research into the effects of ergot alkaloids 
at cellular level has taught us that stimulation of the D^-dopamine receptor 
is critical in the process of lowering prolactin concentration (Ketabian and Calne 
1979). 
However, ergot alkaloids also tend to stimulate D, -receptors and it is thought 
that many of the side effects occur through this stimulation (Ferrari et al. 1982). 
These effects consist mostly of nausea, dizziness and a tendency to orthostatic 
hypotension (Thorner et al. 1980). Unfortunately, bromocriptine has a rather 
short half life of approximately three hours which necessitates frequent drug 
intake to keep blood concentrations at therapeutic levels (Ho and Thorner 1988). 
The undulating concentration in itself may give rise to side effects as may the 
high concentrations reached in the stomach where dopamine receptors are present. 
It therefore became obvious that the development of a new dopamine agonist, 
with a more selective effect at the D2-dopamine receptor level, would be of 
advantage in the treatment of hyperprolactinaemic patients. 
Many such compounds have been tested and in this thesis some results are 
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presented of phase 2 and phase 3 investigations with 2 of the most promising 
new dopaminergic compounds: CQP 201-403 and CV 205-502. 
Initially it was questioned whether patients suffering from hyperprolactinaemia 
should also be treated when there is no desire for pregnancy. At present however, 
it is generally agreed that hyperprolactinaemic subjects with a macro-adenoma 
of the pituitary gland (Molitch et al. 1985), women suffering from infertility 
due to hyperprolactinaemic amenorrhoea (Thorner and Besser 1977, Bergh 1989) 
and men suffering from impotence due to hyperprolactinaemia all need treatment. 
It has also become evident that hyperprolactinaemia (Franks et al. 1978) in 
the absence of macro-adenomas may give rise to unwanted situations such as 
severe bone loss in women due to their hypo-estrogenic state (Klibanski et al. 
1980, Schlechte et al. 1983). It has also been queried as to whether or not 
elevated prolactin levels are a causative factor in the development of benign 
and malignant breast tumours and hyperlipidaemia (Nagasawa et al. 1981, Vorherr 
1986, Pelkonen et al. 1982). 
It seems therefore that the general consensus exists that hyperprolactinaemic 
patients should be treated continuously if the treatment is tolerated reasonably 
well. All these factors underlined the necessity to search for specific, well tolerated 
and safe dopamine agonists. Although bromocriptine itself has proven to be 
extremely safe (Weil 1986) with no long term serious effects on patient or child, 
the side effects have continued to be a problem in a substantial group of patients. 
In our department which has a long tradition in clinical research within the 
field of prolactin and hyperprolactinaemia, we first studied the effectiveness, 
tolerability and safety of the new dopamine agonist CQP 201-402, in three 
dosages (0,01 mg, 0,02 mg and 0,03 mg). CQP, like bromocriptine is an ergot 
alkaloid derivative but it has a substantial longer half life (Grevel et al. 1986). 
The once a day administration of this drug showed a dose dependent prolactin 
suppression in all subjects as compared to placebo. All safety parameters measured 
during this study and during simular studies elsewhere, have indicated that further 
research with this compound could be carried out. However, its side effect profile 
was quite comparable to that of bromocriptine. 
During our research with CQP 201 -403, parallel studies were carried out elsewhe-
re, mainly in Upsala in Sweden, with the compound CV 205-502 (Rasmussen 
et al. 1987, Venitikou et al. 1987). When the data from all these studies were 
compared, both preparations seemed equally effective in their prolactin suppressi-
on capacity and all safety parameters remained normal. However, the side effect 
profile of CV 205-502 was clearly better than that of CQP 201-403, and therefore 
Sandoz, Basle, Switserland, decided to further develop CV 205-502. From a 
theoretical point of view this last compound has several advantages: it is a 
completely computer designed molecule in which the pharmacologists have tried 
to develop a specific D2-dopamine receptor agonist without or with only minor 
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D,-receptor stimulating properties (Nordmann et al. 1985, Glosse et al. 1988). 
In contrast to the other compounds, this is not an ergot alkaloid derivative. 
Like CQP CV has a half life sufficiently long to justify a once daily administra-
tion. Initial experiments on hyperprolactinaemic volunteers with dosages varying 
between 0,01 and 0.09 mg once a day showed a dose dependent prolactin 
suppression with normalisation of prolactinlevels when the higher dosage was 
used (Gaillard et al. 1986) . In the healthy volunteer studies with women and 
men without hyperprolactinaemia CV 205-502 showed a significantly better 
tolerance as compared to CQP and it was therefore to be expected that this 
new drug would be of advantage for hyperprolactinaemic subjects intolerant 
to bromocriptine. 
When synthetizing the drug, the pharmacologists used as basis the linear 
benzo[g]quinoline and substituted this with ergoiine. CV205-502 is therefore 
an octahydrobenzo[g]quinoline (Nordmann et al. 1985). To show the D2-
dopamine receptor stimulation several studies were carried out in many in vitro 
models using both rat and human pituitary cell cultures containing prolactin 
producing cells from adenomas (Gaillard et al. 1989). These studies like others 
also focused on the interaction between the D, and D2-dopamine receptors 
demonstrating the more specific potency to stimulate the last one as compa-
red to bromocriptine. 
The first experiments in human volunteers focused on tolerability and safety 
(Gaillard et al. 1986). Early studies also measured the possible effect of the 
new compound on pituitary production and release of other hormones than 
prolactin: TSH, FSH, LH, ACTH and growth hormone (Brue et al. 1989). 
Eventually the release of both FSH and LH changed but this is due to the 
reactivation of gonadal function and is not specific for the compound. However, 
in acute experiments a slight but significant increase in growth hormone secretion 
could be demonstrated. This was also the case in our study. This effect on growth 
hormone seems to be common for all dopamine agonists (Vance et al. 1987). 
In contrast to other dopamine agonists compounds, the effect of CV 205-502 
on growth hormone secretion is reproducable in time within the same subjects 
(Mieli et al. 1990). As treatment goes on and becomes chronic the growth hormone 
response to provocative stimuli normalizes. In this respect our study is in agreement 
with those carried out by others during the same period. 
During acute CV 205-502 administration the pituitary prolactin response to 
an acute TRH provocation is practically identical in healthy, normoprolactinaemic 
volunteers as compared to hyperprolactinaemic women. This is interesting since 
it has been postulated that dopamine agonists would also block this response 
to TRH. Vemer has shown the same in his studies in puerperal women (Vemer 
1979). It may very well be that during chronic experiments the prolactin response 
to TRH becomes blocked. The reasoning would then be that in an acute experiment 
80 
the dopamine agonist would block the release of prolactin while prolactin is 
still stored within the cell. TRH, when stimulating prolactin release through 
different receptors will then bring about release of the stored prolactin in the 
cell. It is only during chronic dopamine treatment that the cell content of prolactin 
diminishes (Pasteéis 1977). Once this has occurred no further prolactin release 
in response to TRH can take place. 
Several phase 3 studies carried out in a prospective, randomized and double 
blind fashion have compared the effect of bromocriptine and CV 205-502 in 
hyperprolactinaemic women. However, one of the first and most extensive of 
these is the study reported in this thesis. From this it can be concluded that 
CV 205-502 is at least as effective as bromocriptine in its prolactin lowering 
properties. Once normal prolactinaemia is restored both compounds are equally 
effective in restoring the gonadal function and inhibition of galactorrhoea. 
As was to be expected, the toierabiiity of CV 205-502 is better than that of 
bromocriptine. Although in our study this is not clearly demonstrated from the 
number of drop outs in the two groups, the fact that 9 out of 10 patients who 
in the past had shown intolerance to bromocriptine, had accepted CV 205-
502 very well, which strongly argues in favour of the new compound. Furthermore, 
three of four patients who had been considered resistant to bromocriptine 
responded to the new drug with normalization of their prolactin concentrations. 
After our study several reports in agreement with this finding have appeared 
in the literature (Homburg et al. 1990, Newman et al. 1989). 
Although not mentioned in the publications presented in this thesis, several 
casuistic reports from our own group of patients could be added to emphasize 
the broader therapeutic range of CV 205-502 with respect to prolactin sup-
pression: one woman who did not tolerate bromocriptine in amounts of 20 mg 
a day and who did not respond to this dose with normalization of her prolactin 
level, tolerated CV 205-502 without side effects at a dose of 1.1 mg and it 
was only when this dose had been reached that prolactin started to normalize. 
This was followed by a rapid restoring of gonadal function and the occurrence 
of a pregnancy. We, like others, can add several comparable cases to prove 
that from a clinical point of view CV 205-502 is of extreme value (Vance et 
al. 1989, Khalfallah et al. 1990, Barnett et al. 1990, Serri et al. 1990). 
It must be underlined however, that also during CV 205-502 therapy side effects 
may occur, especially at the initiation of treatment. From our studies it seems 
justified to conclude that these side effects are related to the initiation of therapy, 
to the moments when dose increases take place and to the speed by which 
prolactin concentrations decrease. 
In our studies like in others an overall tolerance of approximately 90% or more 
is confirmed during CV 205-502 intake and this is encouraging (Rasmussen 
et al. 1988). 
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In contrast to the studies during the days when bromocriptine was introduced, 
modern trials have much more extensive safety parameters built into their 
protocols with the administration of the new drugs This of course has also 
been the case during experimental CV 205-502 intake None of these safety 
parameters which could show a drug relationship have changed during or after 
drug administration All studies in the literature so far agree on this point 
(Rasmussen et al 1988, Homburg et al 1990) However, we must realize that 
the clinical experience with this new drug is approximately 5 years at the moment 
and we should continue to be cautious This is especially true for women seeking 
treatment tor infertility 
From a theoretical point of view it was not expected that the pregnancy rate 
in CV 205-502 treated women who responded with normalization of their ovarian 
function during treatment would be different from that in bromocriptine treated 
women Indeed studies so far have shown that once ovarian function has restored, 
a normal fertility rate is to be expected Of importance is the fact that animal 
experiments have shown no toxic or teratogenic effects of the new compound 
in dosages far above those needed to influence prolactin release 
Until now 35 pregnancies have been registered The outcome has been reported 
to be normal without suspicion of specific abnormalities related to drug intake 
It goes however without saying that extreme caution has to be maintained 
regarding pregnancy outcome Women suffering from hyperprolactinaemia and 
infertility who use this new compound should be advised to apply mechanical 
contraception until a regular cv^'c ¡us reappeared Thereafter a pregnancy may 
be started and me uuake of CV 205-502 should be discontinued as soon as 
a missed period by a few days is noted The course and the outcome of pregnancy 
must be recorded in the same way as in hyperprolactinaemic women treated 
with bromocriptine for infertility (del Pozo and Darragh 1977, Griffith et al 
1978, Weil 1986) To the best of our knowledge the same guideline has been 
used in all centres where the new compound has been prescribed in phase 3 
and phase 4 trials 
As was to be expected CV 205-502 is very effective in the inhibition of puerperal 
lactation As with bromocriptine (Rolland and Schellekens 1973) it brings about 
a rapid prolactin decrease with a prepregnant range of prolactin concentrations 
within 24 to 48 hours post partum In our study we have prudently started 
with a low dose of the new compound with neglect to the fact that the puerperal 
women during the first or second day of drug intake tolerate the drug generally 
well A starting dose of 0,075 mg seems advisable After withdrawal of CV 
205-502, a prolactin rebound occurred in most women comparable to the 
experience with bromocriptine treated women Several of these women also 
complained of "rebound" breast symptoms Therefore, as for bromocriptine, the 
new compound has to be taken for three weeks to ensure that rebound breast 
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activity does not occur. Preferably however, depot preparations should be made 
available similar to those with bromocriptine (Parlodel1* LA and Parlodel1* LAR). 
Of great interest is the difference in pulse frequency in the two groups of puerperal 
women receiving either bromocriptine or CV 205-502. The last group did not 
show any difference with the control group of breastfeeding women whereas 
bromocriptine treated women showed a significant increase in their pulse rate 
after three minutes of standing. We suggest that the explanation for this difference 
must be based on the more specific D, dopamine receptor stimulating properties 
of CV 205-502 as compared to bromocriptine with at the same time less D, 
dopamine receptor stimulation (Fliickiger et al. 1990). The increase in pulse 
frequency is explained as a tendency to orthostatic hypotension which is 
compensated by an increase in pulse rate. 
Until recently there has been a marked shortage of studies on coagulation and 
fibrinolysis in puerperal women (Beller et al. 1982). We have had the opportunity 
to compare several parameters within these two systems in CV 205-502 treated 
women, bromocriptine treated women and lactating women. Despite the dif-
ferences between the dopamine treated women and the lactating women with 
regard to the restoring of gonadal function, no differences in the measured 
parameters could be observed between the three groups. Although it has been 
suggested that during dopamine treatment a hypercoagulability could occur, we 
have not been able to confirm this. With respect to both coagulation and fibrinolysis 
it is safe to say that the two systems remain in balance during dopamine agonist 
treatment without any sign of hypercoagulation. 
After review of our own studies regarding the clinical testing of new dopamine 
agonists and also after a thorough review of the literature concerning these 
compounds as it has emerged during the last few years, we think that the following 
conclusions can be drawn. 
CQP 201-403 is a potent dopamine agonist with a half life which allows a 
once daily administration. Although the tolerability is reasonable, it compares 
in this respect with bromocriptine. The side effects are similar to those of all 
ergot alkaloid dérivâtes. 
CV 205-502 is the first non ergot alkaloid dopamine agonist showing strong 
prolactin lowering properties. In this respect it is comparable with bromocriptine. 
During exertion of its action it does not influence the acute pituitary response 
of TSH, ACTH, FSH or LH after intravenous administration of releasing 
hormones. The acute effect on growth hormone secretion is comparable with 
that of other dopamine agonists, it is reproducable and it disappears eventually 
during chronic administration. 
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The profile of side effects of CV 205-502 is considerably better than that of 
bromocripti-ne. This explains why the new compound is better tolerated. As 
a consequence the "therapeutic window" of CV 205-502 is significantly greater 
than that of bromocriptine It allows so called dopamine agonist resistant patients 
to be treated adequately. 
CV 205-502 is as effective as bromocriptine in the inhibition of puerperal 
lactation. 
In puerperal women bromocriptine brings about a significant increase in pulse 
frequency after 3 minutes of standing. This increase is absent in CV 205-502 
treated- and lactating- women The explanation for this increase is thought to 
be a compensatory mechanism for orthostatic hypotension. 
The changes that take place in the coagulation and fibrinolysis systems in puerperal 
women are similar in dopamine agonist treated women (bromocriptine and CV 
205-502) and lactating women. 
All safety parameters so far indicate that CV 205-502 is a safe drug. 
Hyperprolactinaemic women treated with CV 205-502 for reasons of infertility 
should be follewed prospectively during and after pregnancy in order to further 
investigate the safety of CV 205-502 with respect to offspring. 
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SUMMARY 
In this thesis the new dopamine agonists CQP 201-403 and CV 205-502 are 
being studied and their efficacy, tolerance and safety in a group of 142 
hyperprolactinaemic women is reported. 
Chapter I gives a survey of the literature. It mentions the history of the hormone 
prolactin, its endocrine regulation patterns and its workingmechanisms. The 
pathophysiology of hyperprolactinaemia and methods of treatment are briefly 
reviewed. 
Chapter 2 describes the effects of CQP 201-403, a propyl-ergolin, in a group 
of 24 hyperprolactinaemic women. In a double blind study three different dosages 
of CQP 201-403 are compared with a placebo. A dose-dependent decrease 
of serum prolactin is observed with a once daily drug administration. With the 
exception of prolactin, none of the other hormonal parameters studied are changed 
significantly. Tolerance is moderate to good and regarding safety parameters, 
no changes that could be drug-related have been observed. Further studies with 
CQP 201-403 have been discontinued for industrial political reasons, but also 
since the tolerance of the second compound is judged to be better. 
Chapter 3 deals with a prospective randomized, double blind placebo controlled 
study with СV 205-502, a octahydrobenzofglquinoline, in 12 hyperprolactinaemic 
patients. 
A combined pituitary challenge test with GnRH, TRH, CRH, and GHRH is 
carried out in two groups of patients, before and after 4 weeks of treatment 
with 0.05 mg of CV 205-502 or a placebo. In the CV treated group a 64% 
decrease of serum prolactin is observed. The prolactin response to CV 205-
502 is blunted after TRH administration, but a tendency towards normalisation 
is shown after 4 weeks of treatment. The reason for this is assumed to be the 
initial block of prolactin secretion from the lactotropic cells, which precedes 
the inhibition of synthesis in these cells. 
The response of GH, TSH, LH, ACTH and Cortisol does not change. FSH, however, 
shows a significant decrease after 4 weeks of CV 205-502 administration. This 
is explained by an increase of oestradiol due to the restoring ovarian function. 
No changes in the hormonal parameters is observed in the placebogroup. 
Chapter 4 describes the efficacy, tolerance and safety of CV 205-502 in increasing 
dosages (maximum 0.150 mg) during a 12 month treatment period in 41 patients. 
The previously described efficacy of this drug is confirmed, as well as the high 
to excellent degree of tolerance and safety during a long period of treatment. 
Patients who have shown bad tolerance towards bromocriptine in the past, 
responded better to CV 205-502 in this study and treatment could be continued. 
In Chapter 5 CV 205-502 is compared with bromocriptine (Parlodel®). After 
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randomization a double blind study is undertaken in 47 women during a period 
of 24 weeks. Both drugs show very good and comparable efficacy. Inthe course 
of treatment, tolerance however, is better in the CV 205-502 group. The degree 
of normalisation of the ovarian function and the disappearance of galactorrhoea 
is equally observed. 
Chapter 6 contains the open comparison of inhibition of lactation in a CV 205-
502 and a bromocriptine treated group next to a control group of lactating 
women. Besides, changes in coagulation and fibrinolysis systems are studied. 
In the group of 20 women who are taking 0.075 mg of CV 205-502 daily, 
a normoprolactinaemic level is reached within 72 hours. Slight breast symptoms 
occur in 15 women, notably on treatment day 3 and 4. In the bromocriptine 
group of 10 women, a prolactin decrease is reached to the same extent within 
the same time. In 3 of these women breast symptoms are registered between 
day 2 and 28. Tolerance in both groups is very good. Only the pulse frequency 
in standing position is significantly increased in the bromocriptine treated group 
compared to the CV treated or the control group. This may be explained by 
a stronger D,-receptor stimulation by bromocriptine thereby inducing orthostatic 
hypotension that is compensated by a higher pulse frequency. Blood coagulation 
studies in the 3 groups show no significant differences. 
In chapter 7 the preceding studies are evaluated and compared existing literature. 
The following conclusions can be drawn: 
- CQP 201-403 is an effective dopamine agonist with a half life which permits 
a once daily administration. Tolerance and side effect profile are comparable 
to those of the known derivatives of ergot alkaloids like bromocriptine. 
- CV 205-502 is the first non ergot alkaloid dopamine agonist. It gives a strong 
prolactin decreasing effect which is comparable to that of bromocriptine. It 
exerts its action without influencing the pituitary-thyroid, pituitary-ovarian 
or pituitary-adrenal axis. The influence on acute GH secretion is similar to 
that of other dopamine agonists. 
- The side effect profile of CV 205-502 is better than that of bromocriptine. 
Consequently CV 205-502 has a larger therapeutic window. 
- CV 205-502 is as effective as bromocriptine regarding inhibition of lactation. 
A significant increase in pulse frequency measured after 3 minutes in standing 
position during the use of bromocriptine is explained as a compensation-
mechanism for orthostatic hypotension. The changes in the coagulation and 
fibrinolysis systems which occur normally in puerperal women, are present 
to the same exent in the groups who use the dopamine agonists studied and 
the group of lactating women. 
- Measured safety parameters indicated that CV 205-502 a safe drug. 
- Women with hyperprolactinaemia, who are treated with CV 205-502 for 
reasons of infertility, should be monitored closely during and after their 
pregnancies as should their off-spring in order to elucidate the safety of CV 
205-502 with relation to mother and child. 
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SAMENVATTING 
In dit proefschrift worden de nieuwe dopamine agonisten CQP 201-403 en CV 
205-502 bestudeerd, waarbij vooral aandacht besteed wordt aan de effectiviteit, 
tolerantie en veiligheid bij 142 vrouwen met een hypcrprolactinaemie. 
Hoofdstuk 1 betreft een overzicht van literatuur gegevens. In eerste instantie 
belicht het de geschiedenis van het hormoon prolactine, daarna volgt een 
bespreking van de endocriene regulatie patronen en werkingsmechanismen. De 
pathofysiologie en behandelingsmethoden van hyperprolactinaemie, tenslotte, 
worden kort uiteengezet. 
Hoofdstuk 2 beschrijft de effecten van CQP 201-403, een propyl-ergoline, in 
24 vrouwen lijdende aan hypcrprolactinaemie. In deze dubbel blinde studie 
worden drie doseringen CQP 201-403 vergeleken met een placebo. Er wordt 
een dosisafhankelijke prolactine verlaging waargenomen bij inname eenmaal 
per dag. Behalve de prolactine spiegel worden geen van de andere bestudeerde, 
hormonale parameters beïnvloed. 
De tolerantie is redelijk tot goed en er treden geen veranderingen in de 
waarnemingen betreffende veiligheid op, die aan het middel moeten worden 
toegeschreven. Om bedrijfspolitieke redenen en vanwege de geconstateerde betere 
tolerantie van CV 205-502 werd afgezien van nadere studies met CQP 201-403. 
Hoofdstuk 3 beschrijft een prospectieve, dubbel blinde, gerandomiseerde, placebo 
gecontroleerde studie met CV 205-502, een octahydrobenzo[g]quinoline, bij 12 
hyperprolactinaemische patiënten. 
In twee groepen van 6 patiënten wordt bij aanvang en na 4 weken behandeling 
met 0,05 mg CV 205-502 of een placebo, een gecombineerde hypofyse 
belastingstest met GnRH, TRH, CRH en GHRH uitgevoerd. 
In de CV groep wordt een daling van de prolactine spiegel van 64% waargenomen. 
De reactie van prolactine na TRH toediening is verminderd voorafgaande aan 
CV 205-502 toediening, maar toont een trend tot normalisatie na 4 weken 
behandeling. Een reden hiervoor moet worden gezocht in de, in eerste instantie, 
optredende blokkade van de secretie van prolactine uit de lactotrofe cel, 
voorafgaande aan de remming van de synthese. De reacties van GH, TSH, LH, 
ACTH en Cortisol veranderen niet. FSH echter toont een significante daling 
na 4 weken behandeling met CV 205-502. De verklaring hiervoor moet worden 
gezocht in de stijging van E2 ten gevolge van een herstellende ovariële functie. 
In de placebogroep kunnen geen veranderingen in de hormonale parameters 
worden vastgesteld. 
Hoofdstuk 4 is een beschrijving van de effectiviteit, tolerantie en veiligheid van 
CV 205-502, bestudeerd tijdens de behandeling van 41 patiënten gedurende 
12 maanden, met oplopende doseringen tot een maximum van 0,150 mg CV 
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205-502. De reeds eerder beschreven goede effectiviteit van dit geneesmiddel 
kon worden bevestigd, evenals de goede tot uitstekende tolerantie en veiligheid 
gedurende langdurige behandeling. Patiënten die in het verleden werden be-
handeld met bromocriptine (Parlodel®) en daarbij een slechte tolerantie ver-
toonden reageerdenin deze studie beter op CV 205-502 en konden derhalve 
doorbehandeld worden. 
Hoofdstuk 5. In deze dubbel blinde studie wordt uiteindelijk CV 205-502 met 
bromocriptine vergeleken. Na randomisatie worden 47 vrouwen met een hy-
perprolactinaemie verzocht, gedurende 24 weken óf CV 205-502 óf bromo-
criptine in te nemen. 
Van beide medicamenten wordt een grote en vergelijkbare effectiviteit vastgesteld. 
De tolerantie blijkt echter in de loop van de behandeling in het voordeel van 
CV 205-502 uit te vallen. Het herstel van de ovariële functie en het verdwijnen 
van de galactorrhoea wordt in gelijke mate waargenomen. 
Hoofdstuk 6 tenslotte behelst een open studie waarbij het lactatieremmend 
vermogen van CV 205-502 wordt vergeleken met dat van bromocriptine. 
Daarnaast is de bloedstolling en de veranderingen hierin onderwerp van studie. 
Een groep van vrouwen die borstvoeding geven dient hierbij als referentie. De 
groep van 20 vrouwen die CV 205-502 gebruiken in een dosering van 0,075 
mg, bereikt binnen 72 uur normale prolactine waarden. Bij 15 vrouwen treden 
geringe tekenen van stuwing op, met name op dag 3 en 4 van inname. In de 
bromocriptine groep van 10 vrouwen wordt in gelijke mate en tijd een prolactine 
daling bereikt. Bij 3 van hen worden eveneens geringe tekenen van stuwing 
geregistreerd tussen dag 2 en 28. De tolerantie is in beide groepen zeer goed. 
Slechts de polsfrequentie in staande positie is in de bromocriptine groep significant 
hoger dan in de CV groep of de controle groep. De verklaring hiervoor berust 
waarschijnlijk op een sterkere Dpreceptor stimulatie door bromocriptine waard-
oor een neiging tot orthostatische hypotensie wordt geïnduceerd. Deze ortho-
statische hypotensie zou dan worden gecompenseerd door een hogere polsfre-
quentie. De testen betreffende coagulatie tonen in de drie groepen geen significante 
verschillen. 
In Hoofdstuk 7 worden de voorafgaande studies geëvalueerd aan de hand van 
bestaande literatuur. 
De volgende conclusies kunnen worden getrokken: 
- CQP 201-403 is een effectieve dopamine agonist, met een halfwaarde tijd 
die een toediening eenmaal per dag toelaat. De tolerantie en het profiel van 
bijwerkingen zijn gelijk aan de bekende ergot alkaloïden derivaten, zoals 
bromocriptine. 
- CV 205-502 is de eerste non-ergot alkaloïde dopamine agonist. Het bezit 
een sterk prolactine verlagend effect, welke vergelijkbaar is met die van 
bromocriptine, zonder invloed uit te oefenen op de hypofyse-schildklier, 
-ovarium of -bijnier as. De invloed op de acute GH-secretie is vergelijkbaar 
met die van andere dopamine agonisten. 
- Het profiel van bijwerkingen van CV 205-502 is gunstiger dan dat van 
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bromocriptine. Een consequentie hiervan is dat de therapeutische breedte van 
CV 205-502 groter is dan dat van bromocriptine. 
- CV 205-502 is even effectief als bromocriptine voor wat betreft lactatierem-
ming. Wel bestaat er een significante stijging van de polsfrequentie stijging 
tijdens bromocriptine gebruik, gemeten na 3 minuten in staande positie. Een 
aannemelijke verklaring lijkt te zijn dat het als compenserendmechanisme 
voor een neiging tot orthostatische hypotensie dient. De veranderingen, die 
optreden in de bloedstolling en fibrinolyses bij vrouwen in het puerperium, 
zijn in gelijke mate aanwezig bij hen die de onderzochte dopamine agonisten 
gebruikten als bij vrouwen, die borstvoeding geven. 
- Alle gemeten parameters betreffende veiligheid geven aan dat CV 205-502 
een veilig geneesmiddel is. 
- Om de veiligheid van CV 205-502 met betrekking tot moeder en kind nader 
te bestuderen, is het noodzakelijk dat zowel de vrouwen, die om reden van 
infertiliteit hiermee behandeld worden, als hun kinderen tijdens en na de 
zwangerschap frequent worden gecontroleerd. 
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Stellingen 
behorende bij het proefschrift 
"New dopamine agonists and hyperprolactinaernia" 
1. De dopamine agonist CV 205-502 is een aanwinst in de 
therapeutische mogelijkheden voor patiënten lijdende aan 
hyperprolactinaemie. 
(dit proefschrift) 
2. De therapeutische breedte van CV 205-502 is groter dan die 
van bromocriptine. 
"^- (dit proefschrift) 
3. Het geconstateerde verschil in polsfrequentie, gemeten na 
drie minuten staan, bij kraamvrouwen tijdens inname van 
bromocriptine danwei CV 205-502, strookt met de theorie dat 
bromocriptine meer Dl-receptor stimulerende eigenschappen 
bezit dan CV 205-502. 
(dit proefschrift) 
4. Het innemen van dopamine agonisten in het kraambed 
beïnvloedt de fysiologische veranderingen niet, die 
optreden in bloedstolling en fibrinolyse post partim. 
(dit proefschrift) 
5. Het is billijk, dat van een candidaat leerling-verpleegster 
eenige algemeene ontwikkeling wordt gevraagd. 
(P.E.G. van der Heijden, thesis 1934) 
6. In de soms fel gevoerde discussie omtrent het al of niet 
geven van borstvoeding wordt weinig aandacht besteed aan 
het positieve effect dat lactatieremming kan hebben op het 
ontstaan van een goede band tussen vader en kind. 
7. Indien moedermelk conform de normen, gesteld in de 
warenwet, wordt beoordeeld op het voorkomen van dioxiden, 
zou het niet mogen worden verkocht. 
8. In de meeste gevallen geldt in de obstetrie, in 
tegenstelling tot in de psychiatrie: je kunt beter 
gescheurd dan geknipt zijn. 
9. Een goede omloop is nooit weg. 
juni 1991 P.F.M, van der Heijden 
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